5,487 Matching Annotations
  1. Oct 2026
    1. 84

      Case#: 84, male, 48 years old, Chinese

      DiseaseAssertion: Hemophilia A, severe

      FamilyInfo: Noted Family History

      ParentalTesting: Maternity confirmed

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C < 1%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: F8 gene variants were identified using next-generation sequencing (NGS), inverse shifting PCR and MLPA

      Gene: F8

      Variant: NM_000132.3:c.5821A>C

      LegacyVariant:

      ClinVar: No

      CAID: CA414906679

      gnomAD:

    2. 20

      Case#: 20, male, 36 years old, Chinese

      DiseaseAssertion: Hemophilia A, severe

      FamilyInfo: Noted Family History

      ParentalTesting: Maternity confirmed

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C < 1%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: F8 gene variants were identified using next-generation sequencing (NGS), inverse shifting PCR and MLPA

      Gene: F8

      Variant: NM_000132.3:c.5953C>T

      LegacyVariant:

      ClinVar: 10300

      CAID: CA255191

      gnomAD:

    1. The ophthalmic phenotype of IFT140-related ciliopathy ranges from isolated to syndromic congenital retinal dystrophy

      PMID: 26359340

      Gene: IFT140

      HGNC: 29077

      Disease: Retinitis pigmentosa 80

      MONDO: 0054708

      InheritancePattern: autosomal recessive

      Prevalence: The overall prevalence of Retinitis pigmentosa is between 1 in 3,000 and 1 in 4,000 individuals, while the proportion of Retinitis pigmentosa with a recessive mode of inheritance is estimated to be 65-85% (between 1 in 3,500 and 1 in 6,500).

      Penetrance: Disease caused by biallelic IFT140 variants appears to be fully penetrant.

    1. Localization of the Functional Domains of Human Tissue Inhibitor of Metalloproteinases-3 and the Effects of a Sorsby's Fundus Dystrophy Mutation

      PMID: 9642234

      Gene: TIMP3

      HGNC: 11822

      Disease: Sorsby fundus dystrophy (SFD), also known as Sorsby's fundus dystrophy, Sorsby pseudoinflammatory fundus dystrophy, or hemorrhagic macular dystrophy

      MONDO: 0007640

      InheritancePattern: Autosomal Dominant

      Prevalence: Estimated at 1 in 220,000 (PMID: 28847738)

      Penetrance: Fully penetrant, onset between the third and sixth decades of life

    1. Mutations in IMPG2, Encoding Interphotoreceptor Matrix Proteoglycan 2, Cause Autosomal-Recessive Retinitis Pigmentosa

      PMID: 20673862

      Gene: IMPG2

      HGNC: 18362

      Disease: retinitis pigmentosa 56

      MONDO: 0013314

      InheritancePattern: semi-dominant

      Prevalence: Vitelliform macular dystrophy in general is estimated to have a prevalence of 1 in 5,500 (PMID: 27120116).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete, while heterozygous carriers of deleterious variants show incomplete penetrance and variable expressivity.

    1. Whole exome sequencing revealed novel pathogenic variants in Vietnamese patients with FEVR

      PMID: 37089697

      Gene: CTNNB1

      HGNC: 2514

      Disease: severe intellectual disability-progressive spastic diplegia syndrome

      MONDO: 0014035

      InheritancePattern: autosomal dominant

      Prevalence: The incidence is unknown but estimated to be between 1 in 30,000 and 1 in 40,000 births (PMID: 32168371).

      Penetrance: The penetrance of the cognitive impairment phenotype among cases appears to be near-complete, while the exudative vitreoretinopathy phenotype reportedly has a prevalence of ~39% among affected individuals with a syndromic diagnosis.

    1. Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa

      PMID: 9501220

      Gene: RPE65

      HGNC: 10294

      Disease: Retinitis pigmentosa 20

      MONDO: 0013425

      InheritancePattern: Autosomal Recessive

      Prevalence: The overall prevalence of Retinitis pigmentosa is between 1 in 3,000 and 1 in 4,000 individuals, while the proportion of recessive Retinitis pigmentosa caused by RPE65 variants is ~2%. (PMID: 9501220) Thus, the prevalence of Retinitis pigmentosa 20 is between 1 in 150,000 and 1 in 200,000.

      Penetrance: Fully penetrant, with onset typically in childhood

    1. Molecular genetic and clinical evaluation of three Chinese families with X-linked ocular albinism

      PMID: 28211458

      Gene: GPR143

      HGNC: 20145

      Disease: X-linked recessive ocular albinism

      MONDO: 0021019

      InheritancePattern: X-linked recessive

      Prevalence: Ocular albinism has an estimated prevalence between 1 in 111,000 and 1 in 1,000,000 live births (PMID: 35495622)

      Penetrance: Fully penetrant in males, with onset in infancy. Most female carriers appear to be unaffected.

    1. Autosomal Recessive Familial Exudative Vitreoretinopathy Is Associated with Mutations in LRP5

      PMID: 15346351

      Gene: LRP5

      HGNC: 6697

      Disease: osteoporosis-pseudoglioma syndrome

      MONDO: 0009820

      InheritancePattern: autosomal recessive

      Prevalence: osteoporosis-pseudoglioma syndrome is estimated to occur in 1 out of every 2,000,000 live births.

      Penetrance: The penetrance of the phenotype among homozygous or compound heterozygous cases appears to be complete, while heterozygous carriers of deleterious variants appear to be mildly affected.

    1. Evidence for a Retroviral Insertion in TRPM1 as the Cause of Congenital Stationary Night Blindness and Leopard Complex Spotting in the Horse

      PMID: 24167615

      Gene: TRPM1

      HGNC: 7146

      Disease: congenital stationary night blindness 1C

      MONDO: MONDO:0013183

      InheritancePattern: autosomal recessive

      Prevalence: Congenital stationary night blindness has an estimated prevalence between 1 in 6,000 (PMID: 31427709) and 1 in 300,000 (PMID: 3487908). However, the prevalence of congenital stationary night blindness 1C specifically is unknown.

      Penetrance: Penetrance is thought to be complete.

    1. RPGR is mutated in patients with a complex X linked phenotype combining primary ciliary dyskinesia and retinitis pigmentosa

      PMID: 16055928

      Gene: RPGR

      HGNC: 10295

      Disease: RPGR-related retinopathy

      MONDO: MONDO:0100437

      InheritancePattern: X-linked

      Prevalence: The prevalence of RPGR-related retinopathy is calculated to be approximately 1 in 214,000, based on the known incidence of retinitis pigmentosa at 1 in 3,000, the proportion of retinitis pigmentposa that is X-linked at 20%, and the proportion of X-linked retinitis pigmentosa that is RPGR-associated at 70% (PMID: 34985506).

      Penetrance: Penetrance is nearly 100% in hemizygous males but is incomplete and dependent upon the variant in heterozygous female carriers.

    1. The Y141C knockin mutation in RDS leads to complex phenotypes in the mouse

      PMID: 25001182

      Gene: PRPH2

      HGNC: 9942

      Disease: retinitis pigmentosa 7

      MONDO: 0011974

      InheritancePattern: semi-dominant

      Prevalence: The incidence of PRPH2-related cases among inherited retinal dystrophies is reported to range from 3.5% in North America to 10.3% in France (PMID: 36010202).

      Penetrance: The penetrance among biallelic cases appears to be complete, while the monoallelic cases exhibit incomplete penetrance (PMID: 36609934).

    1. OA1 mutations and deletions in X-linked ocular albinism.

      PMID: 9529334

      Gene: GPR143

      HGNC: 20145

      Disease: X-linked recessive ocular albinism

      MONDO: 0021019

      InheritancePattern: X-linked recessive

      Prevalence: Ocular albinism has an estimated prevalence between 1 in 111,000 and 1 in 1,000,000 live births (PMID: 35495622)

      Penetrance: Fully penetrant in males, with onset in infancy. Most female carriers appear to be unaffected.

    1. Combined NGS Approaches Identify Mutations in the Intraflagellar Transport Gene IFT140 in Skeletal Ciliopathies with Early Progressive Kidney Disease

      PMID: 23418020

      Gene: IFT140

      HGNC: 29077

      Disease: short-rib thoracic dysplasia 9 with or without polydactyly

      MONDO: 0009964

      InheritancePattern: Autosomal Recessive

      Prevalence: The overall prevalence of short-rib thoracic dysplasia is estimated to be between 1 in 100,000 and 1 in 130,000 births (PMID: 931421).

      Penetrance: Disease caused by biallelic IFT140 variants appears to be fully penetrant.

    1. Mutations in GPR143/OA1 and ABCA4 Inform Interpretations of Short-Wavelength and Near-Infrared Fundus Autofluorescence

      PMID: 29847651

      Gene: GPR143

      HGNC: 20145

      Disease: X-linked recessive ocular albinism

      MONDO: 0021019

      InheritancePattern: X-linked recessive

      Prevalence: Ocular albinism has an estimated prevalence between 1 in 111,000 and 1 in 1,000,000 live births (PMID: 35495622)

      Penetrance: Fully penetrant in males, with onset in infancy. Most female carriers appear to be unaffected.

    1. OCT angiography in the management of choroidal neovascular membrane secondary to Sorsby fundus dystrophy

      PMID: 27587748

      Gene: TIMP3

      HGNC: 11822

      Disease: Sorsby fundus dystrophy (SFD), also known as Sorsby's fundus dystrophy, Sorsby pseudoinflammatory fundus dystrophy, or hemorrhagic macular dystrophy

      MONDO: 0007640

      InheritancePattern: Autosomal Dominant

      Prevalence: Estimated at 1 in 220,000 (PMID: 28847738)

      Penetrance: Fully penetrant, onset between the third and sixth decades of life

    1. Cardiovascular actions of DOPA mediated by the gene product of ocular albinism 1

      PMID: 25185585

      Gene: GPR143

      HGNC: 20145

      Disease: X-linked recessive ocular albinism

      MONDO: 0021019

      InheritancePattern: X-linked recessive

      Prevalence: Ocular albinism has an estimated prevalence between 1 in 111,000 and 1 in 1,000,000 live births (PMID: 35495622)

      Penetrance: Fully penetrant in males, with onset in infancy. Most female carriers appear to be unaffected.

    1. Microarray-Based Mutation Detection and Phenotypic Characterization of Patients with Leber Congenital Amaurosis

      PMID: 16505055

      Gene: GUCY2D

      HGNC: 4689

      Disease: Leber congenital amaurosis 1

      MONDO: 0008764

      InheritancePattern: Autosomal Recessive

      Prevalence: The overall prevalence of Leber congenital amaurosis is between 1 in 33,000 and 1 in 100,000 newborns, while the proportion of Leber congenital amaurosis caused by GUCY2D variants is between 10% and 20% (PMID: 10951519). Thus, the prevalence of Leber congenital amaurosis 1 is between 1 in 165,000 and 1 in 1,000,000.

      Penetrance: Fully penetrant, with onset in neonates or in infancy

    1. Mutations in IMPG1 Cause Vitelliform Macular Dystrophies

      PMID: 23993198

      Gene: IMPG1

      HGNC: 6055

      Disease: vitelliform macular dystrophy 4

      MONDO: 0014508

      InheritancePattern: semi-dominant

      Prevalence: Vitelliform macular dystrophy in general is estimated to have a prevalence of 1 in 5,500 (PMID: 27120116).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete, while heterozygous carriers of deleterious variants show incomplete penetrance and variable expressivity.

    1. Sorsby Fundus Dystrophy Mutation in Tissue Inhibitor of Metalloproteinase 3 (TIMP3) promotes Choroidal Neovascularization via a Fibroblast Growth Factor-dependent Mechanism

      PMID: 31757977

      Gene: TIMP3

      HGNC: 11822

      Disease: Sorsby fundus dystrophy (SFD), also known as Sorsby's fundus dystrophy, Sorsby pseudoinflammatory fundus dystrophy, or hemorrhagic macular dystrophy

      MONDO: 0007640

      InheritancePattern: Autosomal Dominant

      Prevalence: Estimated at 1 in 220,000 (PMID: 28847738)

      Penetrance: Fully penetrant, onset between the third and sixth decades of life

    1. Homozygosity Mapping Reveals PDE6C Mutations in Patients with Early-Onset Cone Photoreceptor Disorders

      PMID: 19615668

      Gene: PDE6C

      HGNC: 8787

      Disease: cone dystrophy 4

      MONDO: 0013129

      InheritancePattern: recessive

      Prevalence: cone dystrophy in general is estimated to have a prevalence of 1 in 40,000 (PMID: 30578485).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete.

    1. Whole Exome Sequencing Reveals GUCY2D as a Major Gene Associated With Cone and Cone–Rod Dystrophy in Israel

      PMID: 25515582

      Gene: GUCY2D

      HGNC: 4689

      Disease: Cone-rod dystrophy 6

      MONDO: 0011143

      InheritancePattern: Autosomal Dominant

      Prevalence: The overall prevalence of cone-rod dystrophy is between 1 in 30,000 and 1 in 40,000 (PMID: 17270046), while the proportion of cone-rod dystrophy caused by GUCY2D variants is between 19% and 23% (PMID: 22183351, PMID: 25515582). Thus, the prevalence of cone-rod dystrophy 6 is between 1 in 130,000 and 1 in 215,000.

      Penetrance: Penetrance is age-dependent, with onset between the 1st and 6th decades of life.

    1. Mutations in the gene PDE6C encoding the catalytic subunit of the cone photoreceptor phosphodiesterase in patients with achromatopsia

      PMID: 30080950

      Gene: PDE6C

      HGNC: 8787

      Disease: cone dystrophy 4

      MONDO: 0013129

      InheritancePattern: recessive

      Prevalence: cone dystrophy in general is estimated to have a prevalence of 1 in 40,000 (PMID: 30578485).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete.

    1. The Function of Guanylate Cyclase 1 and Guanylate Cyclase 2 in Rod and Cone Photoreceptors

      PMID: 17255100

      Gene: GUCY2D

      HGNC: 4689

      Disease: Leber congenital amaurosis 1

      MONDO: 0008764

      InheritancePattern: Autosomal Recessive

      Prevalence: The overall prevalence of Leber congenital amaurosis is between 1 in 33,000 and 1 in 100,000 newborns, while the proportion of Leber congenital amaurosis caused by GUCY2D variants is between 10% and 20% (PMID: 10951519). Thus, the prevalence of Leber congenital amaurosis 1 is between 1 in 165,000 and 1 in 1,000,000.

      Penetrance: Fully penetrant, with onset in neonates or in infancy

    1. Dominant mutations in RP1L1 are responsible for occult macular dystrophy

      PMID: 20826268

      Gene: RP1L1

      HGNC: 15946

      Disease: occult macular dystrophy

      MONDO: 0013316

      InheritancePattern: autosomal dominant

      Prevalence: The prevalence of occult macular dystrophy is "significantly less than one in 10,000 or 100,000 (https://www.reviewofoptometry.com/article/the-best-is-yet-to-come-feb).

      Penetrance: The disease is known to be incompletely penetrant in family members carrying the heterozygous p.Arg45Trp variant (PMID: 20826268).

    1. Identification of a homozygous BBS7 frameshift mutation in two (related) Chinese Miao families with Bardet-Biedl Syndrome

      PMID: 30839500

      Gene: BBS7

      HGNC: 18758

      Disease: Bardet-Biedl syndrome 7

      MONDO: 0014435

      InheritancePattern: autosomal recessive

      Prevalence: The prevalence of BBS7 variants among Bardet-Biedl syndrome cohorts has been reported at 4.2% (PMID: 19402160), while the prevalence of Bardet-Biedl syndrome overall has been estimated between 1 in 13,500 and 1 in 160,000 live births, depending on the population (PMID: 22713813).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete.

    1. Cauli: A Mouse Strain with an Ift140 Mutation That Results in a Skeletal Ciliopathy Modelling Jeune Syndrome

      PMID: 24009529

      Gene: IFT140

      HGNC: 29077

      Disease: Short-rib thoracic dysplasia 9 with or without polydactyly

      MONDO: 0009964

      InheritancePattern: autosomal recessive

      Prevalence: Within the lumped disease entity for this curation, the most prevalent form may be retinitis pigmentosa. The prevalence of Saldino-Mainzer syndrome (one of the synonyms of Short-rib thoracic dysplasia 9) is less than 1 in 1,000,000. The prevalence of Leber congenital amaurosis cases caused by IFT140 variants (PMID: 26216056) is calculated to be less than 1 in 3,000,000. Although IFT140 variants are estimated to be responsible for less than 2% of RP, the prevalence of the overall disorder at 1 in 3,000 or 1 in 4,000 means the frequency of these cases could potentially be higher than 1 in 1,000,000.

      Penetrance: Known variants for this lumped disease entity appear to be completely penetrant, with highly variable phenotypes and age of onset. On the other hand, the split disease entity caused by monoallelic IFT140 variants appears to have incomplete penetrance.

    1. Clinical and whole exome sequencing findings in children from Yunnan Yi minority ethnic group with retinitis pigmentosa: two case reports

      PMID: 37264419

      Gene: PRPF4

      HGNC: 17349

      Disease: retinitis pigmentosa 70

      MONDO: 0014400

      InheritancePattern: autosomal dominant

      Prevalence: The overall prevalence of retinitis pigmentosa is between 1 in 3,000 and 1 in 4,000 individuals, while the proportion of retinitis pigmentosa with a dominant mode of inheritance is estimated to be 15-35% (between 1 in 8,500 and 1 in 27,000). The proportion of that incidence made up by the specific form caused by variants in PRPF4 is not clear.

      Penetrance: Known disease-causing alleles appear to be incompletely penetrant (PMID: 25383878).

    1. IMPG2-associated retinitis pigmentosa displays relatively early macular involvement

      PMID: 24876279

      Gene: IMPG2

      HGNC: 18362

      Disease: retinitis pigmentosa 56

      MONDO: 0013314

      InheritancePattern: semi-dominant

      Prevalence: Vitelliform macular dystrophy in general is estimated to have a prevalence of 1 in 5,500 (PMID: 27120116).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete, while heterozygous carriers of deleterious variants show incomplete penetrance and variable expressivity.

    1. RPGR mutation associated with retinitis pigmentosa, impaired hearing, and sinorespiratory infections

      PMID: 12920075

      Gene: RPGR

      HGNC: 10295

      Disease: RPGR-related retinopathy

      MONDO: MONDO:0100437

      InheritancePattern: X-linked

      Prevalence: The prevalence of RPGR-related retinopathy is calculated to be approximately 1 in 214,000, based on the known incidence of retinitis pigmentosa at 1 in 3,000, the proportion of retinitis pigmentposa that is X-linked at 20%, and the proportion of X-linked retinitis pigmentosa that is RPGR-associated at 70% (PMID: 34985506).

      Penetrance: Penetrance is nearly 100% in hemizygous males but is incomplete and dependent upon the variant in heterozygous female carriers.

    1. The neuronal ceroid lipofuscinosis protein CLN5: new insights into cellular maturation, transport, and consequences of mutations

      PMID: 20052765

      Gene: CLN5

      HGNC: 2076

      Disease: Ceroid lipofuscinosis, neuronal, 5 (also known as Finnish variant late infantile neuronal ceroid lipofuscinosis, neuronal ceroid lipofuscinosis late infantile Finnish variant, or Finnish vLINCL)

      MONDO: 0009745

      InheritancePattern: Autosomal Recessive

      Prevalence: Unknown, but part of a larger group of NCL disorders with a collective prevalence between 1 in 12,500 (PMID:9662406) and 1 in 100,000 (PMID:23374165)

      Penetrance: Fully penetrant, with onset often in the late infantile period but in some cases during early adulthood or even as late as in the 6th decade of life

    1. GUCY2D mutations in a Chinese cohort with autosomal dominant cone or cone–rod dystrophies

      PMID: 26298565

      Gene: GUCY2D

      HGNC: 4689

      Disease: Cone-rod dystrophy 6

      MONDO: 0011143

      InheritancePattern: Autosomal Dominant

      Prevalence: The overall prevalence of cone-rod dystrophy is between 1 in 30,000 and 1 in 40,000 (PMID: 17270046), while the proportion of cone-rod dystrophy caused by GUCY2D variants is between 19% and 23% (PMID: 22183351, PMID: 25515582). Thus, the prevalence of cone-rod dystrophy 6 is between 1 in 130,000 and 1 in 215,000.

      Penetrance: Penetrance is age-dependent, with onset between the 1st and 6th decades of life.

    1. Extracellular matrix component expression in human pluripotent stem cell-derived retinal organoids recapitulates retinogenesis in vivo and reveals an important role for IMPG1 and CD44 in the development of photoreceptors and interphotoreceptor matrix

      PMID: 29777959

      Gene: IMPG1

      HGNC: 6055

      Disease: vitelliform macular dystrophy 4

      MONDO: 0014508

      InheritancePattern: semi-dominant

      Prevalence: Vitelliform macular dystrophy in general is estimated to have a prevalence of 1 in 5,500 (PMID: 27120116).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete, while heterozygous carriers of deleterious variants show incomplete penetrance and variable expressivity.

    1. Clinical features of a novel TIMP-3 mutation causing Sorsby's fundus dystrophy: implications for disease mechanism

      PMID: 11734514

      Gene: TIMP3

      HGNC: 11822

      Disease: Sorsby fundus dystrophy (SFD), also known as Sorsby's fundus dystrophy, Sorsby pseudoinflammatory fundus dystrophy, or hemorrhagic macular dystrophy

      MONDO: 0007640

      InheritancePattern: Autosomal Dominant

      Prevalence: Estimated at 1 in 220,000 (PMID: 28847738)

      Penetrance: Fully penetrant, onset between the third and sixth decades of life

    1. Disruption of a Retinal Guanylyl Cyclase Gene Leads to Cone-Specific Dystrophy and Paradoxical Rod Behavior

      PMID: 10407028

      Gene: GUCY2D

      HGNC: 4689

      Disease: Leber congenital amaurosis 1

      MONDO: 0008764

      InheritancePattern: Autosomal Recessive

      Prevalence: The overall prevalence of Leber congenital amaurosis is between 1 in 33,000 and 1 in 100,000 newborns, while the proportion of Leber congenital amaurosis caused by GUCY2D variants is between 10% and 20% (PMID: 10951519). Thus, the prevalence of Leber congenital amaurosis 1 is between 1 in 165,000 and 1 in 1,000,000.

      Penetrance: Fully penetrant, with onset in neonates or in infancy

    1. Whole Exome Sequencing Analysis Identifies Mutations in LRP5 in Indian Families with Familial Exudative Vitreoretinopathy

      PMID: 27228167

      Gene: LRP5

      HGNC: 6697

      Disease: osteoporosis-pseudoglioma syndrome

      MONDO: 0009820

      InheritancePattern: autosomal recessive

      Prevalence: osteoporosis-pseudoglioma syndrome is estimated to occur in 1 out of every 2,000,000 live births.

      Penetrance: The penetrance of the phenotype among homozygous or compound heterozygous cases appears to be complete, while heterozygous carriers of deleterious variants appear to be mildly affected.

    1. Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13

      PMID: 8659519

      Gene: LRP5

      HGNC: 6697

      Disease: osteoporosis-pseudoglioma syndrome

      MONDO: 0009820

      InheritancePattern: autosomal recessive

      Prevalence: osteoporosis-pseudoglioma syndrome is estimated to occur in 1 out of every 2,000,000 live births.

      Penetrance: The penetrance of the phenotype among homozygous or compound heterozygous cases appears to be complete, while heterozygous carriers of deleterious variants appear to be mildly affected.

    1. Nr2e3-directed transcriptional regulation of genes involved in photoreceptor development and cell-type specific phototransduction

      PMID: 19379737

      Gene: NR2E3

      HGNC: 7974

      Disease: enhanced S-cone syndrome

      MONDO: 0100288

      InheritancePattern: autosomal recessive

      Prevalence: The overall prevalence of enhanced S cone syndrome is <1 in 1,000,000 (PMID: 30900587).

      Penetrance: The penetrance of enhanced S-cone syndrome has been difficult to determine accurately given the rarity of the condition.

    1. EYS, encoding an ortholog of Drosophila spacemaker, is mutated in autosomal recessive retinitis pigmentosa

      PMID: 18836446

      Gene: EYS

      HGNC: 21555

      Disease: Retinitis pigmentosa 25

      MONDO: MONDO:0011272

      InheritancePattern: autosomal recessive

      Prevalence: The overall prevalence of retinitis pigmentosa is between 1 in 3,000 and 1 in 4,000 individuals, while the proportion of retinitis pigmentosa caused by homozygous or compound heterozygous EYS variants is estimated to be 12% in the French population (PMID: 20333770), implying in an overall prevalence between 1 in 25,000 and 1 in 33,000.

      Penetrance: The disease appears to be completely penetrant among published families.

    1. Phenotypic and Genotypic Characterization of RP1L1-Associated Retinopathy

      PMID: 40172514

      Gene: RP1L1

      HGNC: 15946

      Disease: occult macular dystrophy

      MONDO: 0013316

      InheritancePattern: autosomal dominant

      Prevalence: The prevalence of occult macular dystrophy is "significantly less than one in 10,000 or 100,000 (https://www.reviewofoptometry.com/article/the-best-is-yet-to-come-feb).

      Penetrance: The disease is known to be incompletely penetrant in family members carrying the heterozygous p.Arg45Trp variant (PMID: 20826268).

    1. A novel mutation at the N-terminal domain of the TIMP3 gene in Sorsby fundus dystrophy

      PMID: 23023527

      Gene: TIMP3

      HGNC: 11822

      Disease: Sorsby fundus dystrophy (SFD), also known as Sorsby's fundus dystrophy, Sorsby pseudoinflammatory fundus dystrophy, or hemorrhagic macular dystrophy

      MONDO: 0007640

      InheritancePattern: Autosomal Dominant

      Prevalence: Estimated at 1 in 220,000 (PMID: 28847738)

      Penetrance: Fully penetrant, onset between the third and sixth decades of life

    1. A novel TIMP3 mutation associated with a retinitis pigmentosa-like phenotype

      PMID: 32715858

      Gene: TIMP3

      HGNC: 11822

      Disease: Sorsby fundus dystrophy (SFD), also known as Sorsby's fundus dystrophy, Sorsby pseudoinflammatory fundus dystrophy, or hemorrhagic macular dystrophy

      MONDO: 0007640

      InheritancePattern: Autosomal Dominant

      Prevalence: Estimated at 1 in 220,000 (PMID: 28847738)

      Penetrance: Fully penetrant, onset between the third and sixth decades of life

    1. Retinal Development and Pathophysiology in Kcnj13 Knockout Mice

      PMID: 35096838

      Gene: KCNJ13

      HGNC: 6259

      Disease: Leber congenital amaurosis 16

      MONDO: 0013613

      InheritancePattern: autosomal recessive

      Prevalence: The overall prevalence of Leber congenital amaurosis is between 1 in 33,000 and 1 in 100,000 newborns (PMID: 10951519), while the proportion of Leber congenital amaurosis caused by KCNJ13 variants is unknown.

      Penetrance: Known disease-causing alleles appear to be completely penetrant.

    1. Essential and Synergistic Roles of RP1 and RP1L1 in Rod Photoreceptor Axoneme and Retinitis Pigmentosa

      PMID: 19657028

      Gene: RP1L1

      HGNC: 15946

      Disease: occult macular dystrophy

      MONDO: 0013316

      InheritancePattern: autosomal dominant

      Prevalence: The prevalence of occult macular dystrophy is "significantly less than one in 10,000 or 100,000 (https://www.reviewofoptometry.com/article/the-best-is-yet-to-come-feb).

      Penetrance: The disease is known to be incompletely penetrant in family members carrying the heterozygous p.Arg45Trp variant (PMID: 20826268).

    1. Clinical genomics can facilitate countrywide estimation of autosomal recessive disease burden

      PMID: 27124789

      Gene: PDE6C

      HGNC: 8787

      Disease: cone dystrophy 4

      MONDO: 0013129

      InheritancePattern: recessive

      Prevalence: cone dystrophy in general is estimated to have a prevalence of 1 in 40,000 (PMID: 30578485).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete.

    1. Iris hyperpigmentation in a Chinese family with ocular albinism and the GPR143 mutation

      PMID: 19610097

      Gene: GPR143

      HGNC: 20145

      Disease: X-linked recessive ocular albinism

      MONDO: 0021019

      InheritancePattern: X-linked recessive

      Prevalence: Ocular albinism has an estimated prevalence between 1 in 111,000 and 1 in 1,000,000 live births (PMID: 35495622)

      Penetrance: Fully penetrant in males, with onset in infancy. Most female carriers appear to be unaffected.

    1. Ocular albinism: evidence for a defect in an intracellular signal transduction system

      PMID: 10471510

      Gene: GPR143

      HGNC: 20145

      Disease: X-linked recessive ocular albinism

      MONDO: 0021019

      InheritancePattern: X-linked recessive

      Prevalence: Ocular albinism has an estimated prevalence between 1 in 111,000 and 1 in 1,000,000 live births (PMID: 35495622)

      Penetrance: Fully penetrant in males, with onset in infancy. Most female carriers appear to be unaffected.

    1. Characterization of Human Cone Phosphodiesterase-6 Ectopically Expressed in Xenopus laevis Rods

      PMID: 19801642

      Gene: PDE6C

      HGNC: 8787

      Disease: cone dystrophy 4

      MONDO: 0013129

      InheritancePattern: recessive

      Prevalence: cone dystrophy in general is estimated to have a prevalence of 1 in 40,000 (PMID: 30578485).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete.

    1. Sorsby Fundus Dystrophy: Novel Mutations, Novel Phenotypic Characteristics, and Treatment Outcomes

      PMID: 25766588

      Gene: TIMP3

      HGNC: 11822

      Disease: Sorsby fundus dystrophy (SFD), also known as Sorsby's fundus dystrophy, Sorsby pseudoinflammatory fundus dystrophy, or hemorrhagic macular dystrophy

      MONDO: 0007640

      InheritancePattern: Autosomal Dominant

      Prevalence: Estimated at 1 in 220,000 (PMID: 28847738)

      Penetrance: Fully penetrant, onset between the third and sixth decades of life

    1. Australian Cattle Dogs with Neuronal Ceroid Lipofuscinosis are Homozygous for a CLN5 Nonsense Mutation Previously Identified in Border Collies

      PMID: 27203721

      Gene: CLN5

      HGNC: 2076

      Disease: Ceroid lipofuscinosis, neuronal, 5 (also known as Finnish variant late infantile neuronal ceroid lipofuscinosis, neuronal ceroid lipofuscinosis late infantile Finnish variant, or Finnish vLINCL)

      MONDO: 0009745

      InheritancePattern: Autosomal Recessive

      Prevalence: Unknown, but part of a larger group of NCL disorders with a collective prevalence between 1 in 12,500 (PMID:9662406) and 1 in 100,000 (PMID:23374165)

      Penetrance: Fully penetrant, with onset often in the late infantile period but in some cases during early adulthood or even as late as in the 6th decade of life

    1. Proteoglycan IMPG2 Shapes the Interphotoreceptor Matrix and Modulates Vision

      PMID: 32265257

      Gene: IMPG1

      HGNC: 6055

      Disease: vitelliform macular dystrophy 4

      MONDO: 0014508

      InheritancePattern: semi-dominant

      Prevalence: Vitelliform macular dystrophy in general is estimated to have a prevalence of 1 in 5,500 (PMID: 27120116).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete, while heterozygous carriers of deleterious variants show incomplete penetrance and variable expressivity.

    1. The ocular albinism type 1 protein, an intracellular G protein-coupled receptor, regulates melanosome transport in pigment cells

      PMID: 18697795

      Gene: GPR143

      HGNC: 20145

      Disease: X-linked recessive ocular albinism

      MONDO: 0021019

      InheritancePattern: X-linked recessive

      Prevalence: Ocular albinism has an estimated prevalence between 1 in 111,000 and 1 in 1,000,000 live births (PMID: 35495622)

      Penetrance: Fully penetrant in males, with onset in infancy. Most female carriers appear to be unaffected.

    1. NYX (Nyctalopin on Chromosome X), the Gene Mutated in Congenital Stationary Night Blindness, Encodes a Cell Surface Protein

      PMID: 14507859

      Gene: NYX

      HGNC: 8082

      Disease: Congenital stationary night blindness 1A

      MONDO: 0010690

      InheritancePattern: X-linked recessive

      Prevalence: Congenital stationary night blindness has an estimated prevalence between 1 in 6,000 (PMID: 31427709) and 1 in 300,000 (PMID: 3487908). However, the prevalence of congenital stationary night blindness 1A specifically is unknown.

      Penetrance: Penetrance is thought to be complete.

    1. Autosomal dominant pattern dystrophy of the retina associated with a 4-base pair insertion at codon 140 in the peripherin/RDS gene

      PMID: 7710395

      Gene: PRPH2

      HGNC: 9942

      Disease: retinitis pigmentosa 7

      MONDO: 0011974

      InheritancePattern: semi-dominant

      Prevalence: The incidence of PRPH2-related cases among inherited retinal dystrophies is reported to range from 3.5% in North America to 10.3% in France (PMID: 36010202).

      Penetrance: The penetrance among biallelic cases appears to be complete, while the monoallelic cases exhibit incomplete penetrance (PMID: 36609934).

    1. Interaction between G-coupled Protein Receptor 143 and tyrosinase: Implications for understanding Ocular Albinism Type-1

      PMID: 27720922

      Gene: GPR143

      HGNC: 20145

      Disease: X-linked recessive ocular albinism

      MONDO: 0021019

      InheritancePattern: X-linked recessive

      Prevalence: Ocular albinism has an estimated prevalence between 1 in 111,000 and 1 in 1,000,000 live births (PMID: 35495622)

      Penetrance: Fully penetrant in males, with onset in infancy. Most female carriers appear to be unaffected.

    1. Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa

      PMID: 28676737

      Gene: PDE6A

      HGNC: 8785

      Disease: retinitis pigmentosa 43

      MONDO: MONDO:0013437

      InheritancePattern: autosomal recessive

      Prevalence: The overall prevalence of retinitis pigmentosa is between 1 in 3,000 and 1 in 4,000 individuals, while the proportion of retinitis pigmentosa with a recessive mode of inheritance is estimated to be 65-85% (between 1 in 3,500 and 1 in 6,200). Retinitis pigmentosa 43 is considered to be make up 2-5% of these cases, with an overall prevalence estimated between 1 in 70,000 and 1 in 310,000.

      Penetrance: Known disease-causing alleles appear to be completely penetrant.

    1. Retinal dystrophy of Swedish briard/briard-beagle dogs is due to a 4-bp deletion in RPE65

      PMID: 10191083

      Gene: RPE65

      HGNC: 10294

      Disease: Leber congenital amaurosis 2

      MONDO: 0008765

      InheritancePattern: Autosomal Recessive

      Prevalence: The overall prevalence of Leber congenital amaurosis is between 1 in 33,000 and 1 in 100,000 newborns, while the proportion of Leber congenital amaurosis caused by RPE65 variants is between 1% and 16.7%. Thus, the prevalence of Leber congenital amaurosis 2 is between 1 in 200,000 and 1 in 10,000,000.

      Penetrance: Fully penetrant, with onset typically by 1 year of age

    1. A Novel His158Arg Mutation in TIMP3 Causes a Late-Onset Form of Sorsby Fundus Dystrophy

      PMID: 16989765

      Gene: TIMP3

      HGNC: 11822

      Disease: Sorsby fundus dystrophy (SFD), also known as Sorsby's fundus dystrophy, Sorsby pseudoinflammatory fundus dystrophy, or hemorrhagic macular dystrophy

      MONDO: 0007640

      InheritancePattern: Autosomal Dominant

      Prevalence: Estimated at 1 in 220,000 (PMID: 28847738)

      Penetrance: Fully penetrant, onset between the third and sixth decades of life

    1. A gene (RPGR) with homology to the RCC1 guanine nucleotide exchange factor is mutated in X-linked retinitis pigmentosa (RP3)

      PMID: 8673101

      Gene: RPGR

      HGNC: 10295

      Disease: RPGR-related retinopathy

      MONDO: MONDO:0100437

      InheritancePattern: X-linked

      Prevalence: The prevalence of RPGR-related retinopathy is calculated to be approximately 1 in 214,000, based on the known incidence of retinitis pigmentosa at 1 in 3,000, the proportion of retinitis pigmentposa that is X-linked at 20%, and the proportion of X-linked retinitis pigmentosa that is RPGR-associated at 70% (PMID: 34985506).

      Penetrance: Penetrance is nearly 100% in hemizygous males but is incomplete and dependent upon the variant in heterozygous female carriers.

    1. A Dominant Mutation in Rpe65, D477G, Delays Dark Adaptation and Disturbs the Visual Cycle in the Mutant Knock-In Mice

      PMID: 28041994

      Gene: RPE65

      HGNC: 10294

      Disease: Retinitis pigmentosa 87 with choroidal involvement

      MONDO: 0032873

      InheritancePattern: Autosomal Dominant

      Prevalence: The overall prevalence of Retinitis pigmentosa is between 1 in 3,000 and 1 in 4,000 individuals, while the proportion of Retinitis pigmentosa with a dominant mode of inheritance is estimated to be 15-35% (between 1 in 8,000 and 1 in 27,000). The prevalence of Retinitis pigmentosa 87 with choroidal involvement is considered to be much lower.

      Penetrance: Incomplete penetrance, estimated at 80%

    1. Comprehensive molecular diagnosis of 179 Leber congenital amaurosis and juvenile retinitis pigmentosa patients by targeted next generation sequencing

      PMID: 23847139

      Gene: BBS1

      HGNC: 966

      Disease: Bardet-Biedl syndrome 1

      MONDO: 0008854

      InheritancePattern: autosomal recessive

      Prevalence: The prevalence of BBS1 variants among Bardet-Biedl syndrome cohorts has been reported as at least 20% (PMID: 19402160), while the prevalence of Bardet-Biedl syndrome overall has been estimated between 1 in 13,500 and 1 in 160,000 live births, depending on the population (PMID: 22713813).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete.

    1. A family with RP3 type of X-linked retinitis pigmentosa: an association with ciliary abnormalities

      PMID: 1733835

      Gene: RPGR

      HGNC: 10295

      Disease: RPGR-related retinopathy

      MONDO: MONDO:0100437

      InheritancePattern: X-linked

      Prevalence: The prevalence of RPGR-related retinopathy is calculated to be approximately 1 in 214,000, based on the known incidence of retinitis pigmentosa at 1 in 3,000, the proportion of retinitis pigmentposa that is X-linked at 20%, and the proportion of X-linked retinitis pigmentosa that is RPGR-associated at 70% (PMID: 34985506).

      Penetrance: Penetrance is nearly 100% in hemizygous males but is incomplete and dependent upon the variant in heterozygous female carriers.

    1. A homozygous missense mutation in the IRBP gene (RBP3) associated with autosomal recessive retinitis pigmentosa

      PMID: 19074801

      Gene: RBP3

      HGNC: 9921

      Disease: retinitis pigmentosa 66

      MONDO: 0014093

      InheritancePattern: autosomal recessive

      Prevalence: RBP3-related cases are believed to be very rare (possibly with estimated prevalence of less than 1 in 1,000,000), however, it is believed that there may be under-diagnosis (PMID: 37806543).

      Penetrance: RBP3 disease-causing variants appear to have complete penetrance.

    1. The complete form of X-linked congenital stationary night blindness is caused by mutations in a gene encoding a leucine-rich repeat protein

      PMID: 11062472

      Gene: NYX

      HGNC: 8082

      Disease: Congenital stationary night blindness 1A

      MONDO: 0010690

      InheritancePattern: X-linked recessive

      Prevalence: Congenital stationary night blindness has an estimated prevalence between 1 in 6,000 (PMID: 31427709) and 1 in 300,000 (PMID: 3487908). However, the prevalence of congenital stationary night blindness 1A specifically is unknown.

      Penetrance: Penetrance is thought to be complete.

    1. A null mutation in CABP4 causes Leber's congenital amaurosis-like phenotype

      PMID: 20157620

      Gene: CABP4

      HGNC: 1386

      Disease: cone-rod synaptic disorder, congenital nonprogressive

      MONDO: 0012490

      InheritancePattern: autosomal recessive

      Prevalence: The prevalence of the Åland eye disease or incomplete congenital stationary night blindness phenotype was estimated at 1 in 22,000 based on a Danish male cohort, with CABP4 variants specifically responsible for 1 out of 35 cases (PMID: 28002560).

      Penetrance: Penetrance appears to be 100% among the reported individuals harboring biallelic disease-causing CABP4 variants.

    1. Long-Term Preservation of Cones and Improvement in Visual Function Following Gene Therapy in a Mouse Model of Leber Congenital Amaurosis Caused by Guanylate Cyclase-1 Deficiency

      PMID: 21671801

      Gene: GUCY2D

      HGNC: 4689

      Disease: Leber congenital amaurosis 1

      MONDO: 0008764

      InheritancePattern: Autosomal Recessive

      Prevalence: The overall prevalence of Leber congenital amaurosis is between 1 in 33,000 and 1 in 100,000 newborns, while the proportion of Leber congenital amaurosis caused by GUCY2D variants is between 10% and 20% (PMID: 10951519). Thus, the prevalence of Leber congenital amaurosis 1 is between 1 in 165,000 and 1 in 1,000,000.

      Penetrance: Fully penetrant, with onset in neonates or in infancy

    1. A three-base-pair deletion in the peripherin-RDS gene in one form of retinitis pigmentosa

      PMID: 1749427

      Gene: PRPH2

      HGNC: 9942

      Disease: retinitis pigmentosa 7

      MONDO: 0011974

      InheritancePattern: semi-dominant

      Prevalence: The incidence of PRPH2-related cases among inherited retinal dystrophies is reported to range from 3.5% in North America to 10.3% in France (PMID: 36010202).

      Penetrance: The penetrance among biallelic cases appears to be complete, while the monoallelic cases exhibit incomplete penetrance (PMID: 36609934).

    1. Identification of Compound Heterozygous Mutations in the BBS7 Gene in a Korean Family with Bardet-Biedl Syndrome

      PMID: 25553308

      Gene: BBS7

      HGNC: 18758

      Disease: Bardet-Biedl syndrome 7

      MONDO: 0014435

      InheritancePattern: autosomal recessive

      Prevalence: The prevalence of BBS7 variants among Bardet-Biedl syndrome cohorts has been reported at 4.2% (PMID: 19402160), while the prevalence of Bardet-Biedl syndrome overall has been estimated between 1 in 13,500 and 1 in 160,000 live births, depending on the population (PMID: 22713813).

      Penetrance: The penetrance of the phenotype among homozygous cases appears to be complete.

    1. Analysis of Retinol Binding Protein 4 and ABCA4 Gene Variation in Non-Neovascular Age-Related Macular Degeneration

      PMID: 37510153

      Gene: ABCA4

      HGNC: 34

      Disease: age related macular degeneration 2

      MONDO: 0007932

      InheritancePattern: autosomal dominant

      Prevalence: The overall prevalence of age-related macular degeneration is estimated to be 9.9-19.5% (early-stage) or 1.1-3.9% (late-stage) among all people over age 50 years (PMID: 31712255).

      Penetrance: The penetrance of proposed disease-causing alleles is not clear but is expected to be incomplete and age-dependent.

    1. Novel ADAM9 homozygous mutation in a consanguineous Egyptian family with severe cone-rod dystrophy and cataract

      PMID: 25091951

      Gene: ADAM9

      HGNC: 216

      Disease: cone-rod dystrophy 9

      MONDO: MONDO:0013002

      InheritancePattern: autosomal recessive

      Prevalence: The prevalence of cone-rod dystrophy in general is estimated to be 1 in 40,000 (PMID: 17270046), however, the specific prevalence of cone-rod dystrophy 9 is unknown.

      Penetrance: Penetrance appears to be complete in reported families, but it is possible that incomplete penetrance may be associated with some variants.

    1. Expanded Retinal Disease Spectrum Associated With Autosomal Recessive Mutations in GUCY2D

      PMID: 29559409

      Gene: GUCY2D

      HGNC: 4689

      Disease: Leber congenital amaurosis 1

      MONDO: 0008764

      InheritancePattern: Autosomal Recessive

      Prevalence: The overall prevalence of Leber congenital amaurosis is between 1 in 33,000 and 1 in 100,000 newborns, while the proportion of Leber congenital amaurosis caused by GUCY2D variants is between 10% and 20% (PMID: 10951519). Thus, the prevalence of Leber congenital amaurosis 1 is between 1 in 165,000 and 1 in 1,000,000.

      Penetrance: Fully penetrant, with onset in neonates or in infancy

    1. Disruption of IFT Complex A Causes Cystic Kidneys without Mitotic Spindle Misorientation

      PMID: 22282595

      Gene: IFT140

      HGNC: 29077

      Disease: polycystic kidney disease

      MONDO: 0020642

      InheritancePattern: autosomal dominant

      Prevalence: The overall prevalence of polycystic kidney disease is between 1 in 400 and 1 in 1,000 individuals (PMID: 30523303).

      Penetrance: Disease caused by monoallelic IFT140 variants is incompletely penetrant.

    1. Case#: 02059, Age 38, Male, Blood type A+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: Patient is a member of family # 02059. There is one other member of the family (patient 02060). 02060 has the same exonic variant (c.3614G>A), but has a different intronic variant ( c.7438-169G>A).

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding score 12, VWF:Ag: 5.4, VWF:RCo: 6.1, FVIII:C:11, VWF:CB: 4.5

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant: NM_000552.4:c.3614G>A (p.Arg1205His) and

      ClinVar: 308 ClinVar

      CAID: CA114160 CAID1

      gnomAD:

    2. Case#: 02001, Age 63, Female, Blood Type A+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo:( Family 0201) 8 family members were included in the study. All of them had type VWD type 1. All had the same variant besides patient 02019.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 14, VWF:Ag: 9.7, VWF:RCo: 2.6, FVIII:C: 19, VWF:CB: 6

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.3614G>A (p.Arg1205His)

      ClinVar: 308 ClinVar

      CAID: CA114160

      CAID

      gnomAD: N/A

    3. Case#: 02069, Age 45, Female, Blood Type O+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patients was 1 of 3 members of family #0226.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 5, VWF:Ag: 30, VWF:RCo:27, FVIII:C: 81, VWF:CB: 40

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant: NM_000552.4:c.3467C>T (p.Thr1156Met) and NM_000552.3:c.-3151T>G

      ClinVar: 100264 ClinVar

      CAID: CA228414 CAID

      gnomAD: N/A

    4. Case#: 27030, Age 23, Male, Blood Type O+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is one of 6 members in Family #2703. All members have the same variant.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: VWF:Ag:26, VWF:RCo:28.6, FVIII:C:81, VWF:CB: 30

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Bleeding Score 2

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.1533+15G>A (p.=)

      ClinVar: 100182 ClinVar

      CAID: CA228275 CAID

      gnomAD: MAF of 0.002649 ( 93/ 35104 alleles) in the Latino Population. gnomAD

    5. Case#: 01037, Age 16, Male, Blood Type O- (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: Not listed

      Parental Genotype: Not listed

      CasePresentingHPOs:

      CaseHPOFreeText: Bleeding type 14, VWF:Ag: 22, VWF:RCO: 32, FVIII:C: 28, VWF:CB: 22

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.3426T>C (p.Cys1142=) and NM_000552.4:c.3485_3486inv (p.Pro1162Leu)

      ClinVar: 256668 and 619934

      ClinVar1 ClinVar2

      CAID: CA6402757 and CA658683073

      CAID1 CAID2

      gnomAD: MAF of 0.2228 (2240/10052 alleles) in the African population (CA6402757).

      gnomAD1

    6. Case#: 03015, Age 37, Female, Blood Type O+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: Patient is the only member of family #0399.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding score 0, VWF:Ag: 17, VWF:RCo: 17.7, FVIII:C 15, VWF:CB 16

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant: Not determined

      ClinVar: N/A

      CAID: N/A

      gnomAD: N/A

    7. Case#: 10013, Age 23, Female, Blood Type O+ (Table S3)

      Disease Assertion: VWD1

      FamilyInfo: The patient is the only member of Family#1011.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 3, VWF:Ag:7.2, VWF:RCo:5.6, FVIII:C:19, VWF:CB:6.5

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant: NM_000552.4:c.5198T>C (p.Leu1733Pro)

      ClinVar: N/A

      CAID: CA383496267 CAID

      gnomAD: N/A

    8. Case#: 02047, Age 71, Male, Blood Type: O+ (Table S3)

      Disease Assertion:VWD 1

      FamilyInfo: Family# 0218; 3 Family members were included in the study. All 3 members had VWD type 1. All 3 have the same variant as patient 02047.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 9, VWF:Ag: 9.3, VWF:RCo:6.4, FVIII:C: 30, VWF:CB: 6.1

      CaseNotHPOs:N/A

      CaseNotHPOFreeText:N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.5471C>A (p.Pro1824His)

      ClinVar: 100430 ClinVar

      CAID:CA228725

      CAID

      gnomAD: N/A

    9. Case#: 32010, Age 21, Male, Blood Type not determined (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is one of two members of Family#3210. The second member is a carrier of the variant c.3931C>T.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 12, VWF:Ag:7.2, VWF:RCo: 5.7, FVIII:C: 21, VWF:CB: 6.8

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.3931C>T (p.Gln1311Ter) and NM_000552.4:c.55G>A (p.Gly19Arg)

      ClinVar: 100307 and 100432 ClinVar1 ClinVar

      CAID: CA228496 and CA228729 CAID1 CAID2

      gnomAD: MAF of 0.0003921 (12/ 30604 alleles) in the South Asian population (CA228496). gnomAD

      MAF of 0.0008819 (27/ 30616 alleles) in the South Asian population.

      gnomAD

    10. Case#: 06002, Age 39, Female,Blood Type O+ (Table S3)

      Disease Assertion: VWD1

      FamilyInfo: Two total members in Family #0602. Patient 06003 has the c.2685G>C variant and a seperate intronic variant.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding score 8, VWF:Ag: 25, VWF:RCo: 19.1, FVIII:C:88, VWF:CB:24

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant: NM_000552.4:c.2685G>C (p.Gln895His) and NM_000552.4:c.4751A>G (p.Tyr1584Cys)

      ClinVar: 310

      ClinVar

      CAID: CA383519910 and CA114162

      CAID1 CAID2

      gnomAD: MAF of 0.004024 (519/128972 alleles) in the European (non-Finnish) population.

      gnomAD

    1. 113< 1< 14−−21Fc.2435delC/c.7514C>Ap.P812RfsX31/p.S2505X18/4418/19PD/N

      Case: Patient 11, F, Hungarian

      DiseaseAssertion: VWD type 3

      FamilyInfo: compatible with recessive inheritance

      ParentalGenotype(s): n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeRext: Bleeding score: 21, VWF:Ag (IU dL−1): < 1, VWF:CB (IU dL−1): < 1, FVIII:C (IU dL−1): 4, VWF:RCo below detection limit (<10 IU dL−1), not detectable VWF on multimer gels, bleeding episode severity increased after the menarche

      CaseNOTHPOs: n/a

      CaseNOTHPOFreeText: no inhibitor detected, did not become refractory to factor replacement therapy

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.2435delC (p.Pro812ArgfsX31), Exon 18

      c.7514C>A (p.Ser2505X), Exon 44

      Intron 40 VNTR: 18/19

      Note: multimer electrophoresis, Recombinant VWF antigen concentrations and Collagen binding activity (VWF:CB) measured by ELISA, direct sequencing of the 51 exons and the exon‐intron boundaries, Breakpoint analysis and breakpoint‐specific PCR

    2. 213115LMWM−15Mc.1868G>A/c.3712C>Tp.C623T/p.Q1238X15/2816/17N/N

      Case: Patient 21, M, Hungarian

      DiseaseAssertion: VWD type 3

      FamilyInfo: compatible with recessive inheritance

      ParentalGenotype(s): n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeRext: Bleeding score: 15, VWF:Ag (IU dL−1): 1, VWF:CB (IU dL−1): 1, FVIII:C (IU dL−1): 5, VWF:RCo below detection limit (<10 IU dL−1), low‐molecular‐weight multimer on multimer gels

      CaseNOTHPOs: n/a

      CaseNOTHPOFreeText: no inhibitor detected, did not become refractory to factor replacement therapy

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.1868G>A (p.Cys623Thr), Exon 15

      c.3712C>T (p.Gln1238X), Exon 28

      Intron 40 VNTR: 16/17

      Note: multimer electrophoresis, Recombinant VWF antigen concentrations and Collagen binding activity (VWF:CB) measured by ELISA, direct sequencing of the 51 exons and the exon‐intron boundaries, Breakpoint analysis and breakpoint‐specific PCR

    3. 93113−−10Fc.2435delC/c.5557C>Tp.P812RfsX31/p.R1853X18/3216/19PD/PD

      Case: Patient 9, F, Hungarian

      DiseaseAssertion: VWD type 3

      FamilyInfo: compatible with recessive inheritance

      ParentalGenotype(s): n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeRext: Bleeding score: 10, VWF:Ag (IU dL−1): 1, VWF:CB (IU dL−1): 1, FVIII:C (IU dL−1): 3, VWF:RCo below detection limit (<10 IU dL−1), not detectable VWF on multimer gels, bleeding episode severity increased after the menarche

      CaseNOTHPOs: n/a

      CaseNOTHPOFreeText: no inhibitor detected, did not become refractory to factor replacement therapy

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.2435delC (p.Pro812ArgfsX31), Exon 18

      c.5557C>T (p.Arg1853X), Exon 32

      Intron 40 VNTR: 16/19

      Note: multimer electrophoresis, Recombinant VWF antigen concentrations and Collagen binding activity (VWF:CB) measured by ELISA, direct sequencing of the 51 exons and the exon‐intron boundaries, Breakpoint analysis and breakpoint‐specific PCR

    4. 23< 1110−−23FdelEx1‐3/c.2435delCdelEx1‐3/p.P812RfsX311–3/1818/19N/PD

      Case: Patient 2, F, Hungarian

      DiseaseAssertion: VWD type 3

      FamilyInfo: compatible with recessive inheritance

      ParentalGenotype(s): n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeRext: Bleeding score: 23, VWF:Ag (IU dL−1): < 1, VWF:CB (IU dL−1): 1, FVIII:C (IU dL−1): 10, VWF:RCo below detection limit (<10 IU dL−1), not detectable VWF on multimer gels, bleeding episode severity increased after the menarche

      CaseNOTHPOs: n/a

      CaseNOTHPOFreeText: no inhibitor detected, did not become refractory to factor replacement therapy

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      delEx1‐3 (delEx1‐3), Exon 1–3

      c.2435delC (p.Pro812ArgfsX31), Exon 18

      Intron 40 VNTR: 18/19

      Note: multimer electrophoresis, Recombinant VWF antigen concentrations and Collagen binding activity (VWF:CB) measured by ELISA, direct sequencing of the 51 exons and the exon‐intron boundaries, Breakpoint analysis and breakpoint‐specific PCR

    1. 63 14 M 28 c.3931C.T p.Q1311* Hmz 7.5 ,1 16 - +c.4027A.G p.I1343Vc.4079T.C p.V1360A

      Case: 63, M, 14 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 7.5, VWF:Ag (U/dl): <1, Bleeding Score: 16

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.3931C>T (p.Gln1311*), Exon 28

      c.4027A>G (p.Ile1343Val), Exon 28

      c.4079T>C (p.Val1360Ala), Exon 28

      Homozygous

    2. 89 16 F 28 c.4525A.G p.I1509V C.Htz 3.9 3 16 - -

      Case: 89, F, 16 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 3.9, VWF:Ag (U/dl): 3, Bleeding Score: 16

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.4525A>G (p.Ile1509Val), Exon 28

      Compound Heterozygous

    3. 33 4.5 M 22 c.2908delCp.L970del Hmz 2.3 ,1 10 - -

      Case: 33, M, 4.5 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 2.3, VWF:Ag (U/dl): <1, Bleeding Score: 10

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.2908delC (p.Leu970del), Exon 22, Homozygous

    4. 27 16 F 45 c.7651C.Tp.Q2551* Hmz 2 3.6 11 - +

      Case: 27, F, 16 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: yes, no family history of disease

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 2, VWF:Ag (U/dl): 3.6, Bleeding Score: 11

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.7651C>T (p.Gln2551*), Exon 45, Homozygous

    1. 125

      Case#: Ahmad_2014_125

      DiseaseAssertion: VWD type 2A

      FamilyInfo: heterozygous (probably affected according to multimer analysis) mother

      ParentalGenotype: heterozygous mother, homozygous wt father and sibling

      CasePresentingHPOs: none described

      CaseHPOFreeText: none described

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: PCR, restriction digest

      Gene: VWF

      Variant: NM_000552.5(VWF):c.4883T>C (p.Ile1628Thr)

      HGVS:

      ClinVarID: 284

      CAID:

      gnomAD: not reported

      MultipleGeneVariants:

    1. P2

      Case: P2, male, 32yo

      DiseaseAssertion: VWD2M

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147, HP:0030129, HP:0030130

      (Reduced quantity of VWF, Impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity)

      CaseHPOFreeText: bleeding score = 7; VWF:Ag (%) = 32, VWF:RCo(%) = 19, VWF:RCo/VWF:Ag ratio = 0.59, VWF:CIIIB (%) = 35, VWF:CIIIB/VWF:Ag ratio = 1.09, VWF:CVIB (%) = 32, VWF:CVIB/VWF:Ag ratio = 1.00

      CaseNOTHPOs: HP:0030132

      (Absence of large von Willebrand factor multimers)

      CaseNOTHPOFreeText: NA

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: If applicable.

      Gene: VWF

      Variant: c.4117G>T (p.Asp1373Tyr)

      HGVS: NM_000552.3:c.4117G>T (p.Asp1373Tyr)

      ClinVarID: NA

      CAID: CA383504503; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383504503

      gnomAD: MAF = 0.00002891 (1/34588 alleles) in Latino/AdMixed American population; https://gnomad.broadinstitute.org/variant/12-6128467-C-A

    2. P8

      Case: Patient 8, male, 9yo

      DiseaseAssertion: VWD2M

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030129, HP:0030130

      (Impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity)

      CaseHPOFreeText: bleeding score = 3; VWF:Ag (%) = 57, VWF:RCo(%) = 43, VWF:RCo/VWF:Ag ratio = 0.75, VWF:CIIIB (%) = 35, VWF:CIIIB/VWF:Ag ratio = 0.61, VWF:CVIB (%) = 18, VWF:CVIB/VWF:Ag ratio = 0.32

      CaseNOTHPOs: HP:0030132

      (Absence of large von Willebrand factor multimers)

      CaseNOTHPOFreeText: NA

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.4196G>A

      HGVS: NM_000552.5(VWF):c.4196G>A

      ClinVarID: 293; https://www.ncbi.nlm.nih.gov/clinvar/variation/293/

      CAID:

      gnomAD: MAF = 0.01670 (173/10360 alleles) in the Ashkenazi Jewish population; https://gnomad.broadinstitute.org/variant/12-6128388-C-T?dataset=gnomad_r2_1

    1. T114M/4780.030.020.05c.7399C>T, c.8418_8419insTCCCp.Gln2467*, p.Ser2807 fs43/52Compound heterozygous

      Case: T114, M, 48

      DiseaseAssertion: VWD type 37 FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 8 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.03, VWF:RCo (IU/ml): 0.02, FVIII:C (IU/ml): 0.05

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.7399C>T (p.Gln2467*), Exon 43

      c.8418_8419insTCCC (p.Ser2807 fs), Exon 52

      Compound heterozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    2. T015M/7280.020.020.07c.8418_8419insTCCCp.Ser2807 fs52Homozygous

      Case: T015, M, 72

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 8 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.02, VWF:RCo (IU/ml): 0.02, FVIII:C (IU/ml): 0.07

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.8418_8419insTCCC (p.Ser2807 fs), Exon 52, Homozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    3. T040F/4110.010.030.01c.874 + 5 G>A-7Homozygous

      Case: T040, F, 4

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 11 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.01, VWF:RCo (IU/ml): 0.03, FVIII:C (IU/ml) : 0.01

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.874 + 5 G>A, Exon 7, Homozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    4. T143F/64240.040.040.03c.8043_8044delAGp.Arg2681 fs49Heterozygous

      Case: T143, F, 64

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 24 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.04, VWF:RCo (IU/ml): 0.04, FVIII:C (IU/ml): 0.03

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.8043_8044delAG (p.Arg2681 fs), Exon 49, Heterozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    5. T076M/12230.010.030.01c.1897T>Cp.Cys633Arg15Homozygous

      Case: T076, M, 12

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 23 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.01, VWF:RCo (IU/ml): 0.03, FVIII:C (IU/ml): 0.01

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.1897T>C (p.Cys633Arg ), Exon 15, Homozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    6. T006B

      Case: T006B, F, 11

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 11 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.01, VWF:RCo (IU/ml): 0.01, FVIII:C (IU/ml) : 0.02

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.4006C>T (p.Arg1336*), Exon 28, Homozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequecning of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    1. 33 K

      Case: Patient 33, Family K (Table 1.), F/49, Afro-Caribbean

      DiseaseAssertion: VWD2A (IIE)

      FamilyInfo: Patient 18 (F/53, Afro-Caribbean), Patient 29 (F/33, Afro-Caribbean), Patient 32 (F/17, Afro-Caribbean) also from Family K. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT =17, FVIII:C (IU/dL) = 3, VWF:Ag (IU/dL) = 3, VWF:Act (IU/dL) = 7

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood type A+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.1661del, p.(Lys554Serfs*23)

      HGVS: NM_000552.5:c.1661del (p.Lys554Serfs*23)

      ClinVarID:

      CAID: CA2617232671

      gnomAD: MAF is 0.00001332 (1/75048 alleles) in African/African/American population https://gnomad.broadinstitute.org/variant/chr12-6057916-CT-C?dataset=gnomad_r4

      Variant: c.2365A > G, p.(Thr789Ala)

      HGVS: NM_000552.5:c.2365A>G (p.Thr789Ala)

      ClinVarID: 256659

      CAID: CA6403090

      gnomAD: MAF of 0.5793 (43409/74928 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6044368-T-C?dataset=gnomad_r4

      Variant: c.2385T > C, p.(Tyr795 =)

      HGVS: NM_000552.5:c.2385T>C (p.Tyr795=)

      ClinVarID: 256660

      CAID: CA6403087

      gnomAD: MAF of 0.5788 (43385/74952 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6044348-A-G?dataset=gnomad_r4

      Variant: c.2880G > A, p.(Arg960 =)

      HGVS: NM_000552.5:c.2880G>A (p.Arg960=)

      ClinVarID: 195657

      CAID: CA201877

      gnomAD: MAF of 0.3169 (23737/74896 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6029429-C-T?dataset=gnomad_r4

      Variant: c.3505T > A, p.(Cys1169Ser)

      HGVS: NM_000552.5:c.3505T>A (p.Cys1169Ser)

      ClinVarID:

      CAID: CA383511219

      gnomAD:

      Variant: c.4138A > G, p.(Ile1380Val)

      HGVS: NM_000552.5:c.4138A>G (p.Ile1380Val)

      ClinVarID: 310063

      CAID: CA6402595

      gnomAD: MAF of 0.1184 (8878/74958 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019280-T-C?dataset=gnomad_r4

      Variant: c.4304A > G, p.(Asn1435Ser)

      HGVS: NM_000552.5:c.4304A>G (p.Asn1435Ser)

      ClinVarID: 310062

      CAID: CA6402552

      gnomAD: MAF of 0.1124 (8427/74964 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019114-T-C?dataset=gnomad_r4

      Variant: c.4414G > C p.(Asp1472His)

      HGVS: NM_000552.5:c.4414G>C (p.Asp1472His)

      ClinVarID: 256679

      CAID: CA6402534

      gnomAD: MAF of 0.5076 (38011/74882 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019004-C-G?dataset=gnomad_r4

      Variant: c.6554G > A, p.(Arg2185Gln)

      HGVS: NM_000552.5:c.6554G>A (p.Arg2185Gln)

      ClinVarID: 100443

      CAID: CA228748

      gnomAD: MAF of 0.1927 (14427/74878 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-5993906-C-T?dataset=gnomad_r4

    2. 29 K

      Case: Patient 29, Family K (Table 1.), F/33, Afro-Caribbean

      DiseaseAssertion: VWD2A (IIE)

      FamilyInfo: Patient 18 (F/53, Afro-Caribbean), Patient 32 (F/17, Afro-Caribbean), Patient 33 (F/49, Afro-Caribbean) also from Family K. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT =13, FVIII:C (IU/dL) = 75, VWF:Ag (IU/dL) = 25, VWF:Act (IU/dL) = 18

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood type O+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3505T > A, p.(Cys1169Ser)

      HGVS: NM_000552.5:c.3505T>A (p.Cys1169Ser)

      ClinVarID:

      CAID: CA383511219

      gnomAD:

      Variant: c.4138A > G, p.(Ile1380Val)

      HGVS: NM_000552.5:c.4138A>G (p.Ile1380Val)

      ClinVarID: 310063

      CAID: CA6402595

      gnomAD: MAF of 0.1184 (8878/74958 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019280-T-C?dataset=gnomad_r4

      Variant: c.4304A > G, p.(Asn1435Ser)

      HGVS: NM_000552.5:c.4304A>G (p.Asn1435Ser)

      ClinVarID: 310062

      CAID: CA6402552

      gnomAD: MAF of 0.1124 (8427/74964 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019114-T-C?dataset=gnomad_r4

      Variant: c.4414G > C p.(Asp1472His)

      HGVS: NM_000552.5:c.4414G>C (p.Asp1472His)

      ClinVarID: 256679

      CAID: CA6402534

      gnomAD: MAF of 0.5076 (38011/74882 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019004-C-G?dataset=gnomad_r4

    3. 31 O

      Case: Patient 31, Family O (Table 1.), F/73, Afro-Caribbean

      DiseaseAssertion: VWD2A (IIE)

      FamilyInfo: Patient 30 (M/42, Afro-Caribbean) also from Family O. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT = 2, FVIII:C (IU/dL) = 31, VWF:Ag (IU/dL) = 20, VWF:Act (IU/dL) = 22

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood group O+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.1530G > A, p.(Val510 =) p.

      HGVS: NM_000552.5:c.1530G>A (p.Val510=)

      ClinVarID:

      CAID: CA6403368

      gnomAD: MAF of 0.00002198 (2/91004 alleles) in South Asian population https://gnomad.broadinstitute.org/variant/chr12-6062957-C-T?dataset=gnomad_r4

      Variant: c.1892C > T, p.(Ala631Val)

      HGVS: NM_000552.5:c.1892C>T (p.Ala631Val)

      ClinVarID: 422844

      CAID: CA6403245

      gnomAD: MAF of 0.001908 (137/71810 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6056910-G-A?dataset=gnomad_r4

      Variant: c.2220G > A, p.(Met740Ile)

      HGVS: NM_000552.5:c.2220G>A (p.Met740Ile)

      ClinVarID: 100206

      CAID: CA201316

      gnomAD: MAF of 0.1816 (13626/75022 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6046784-C-T?dataset=gnomad_r4

      Variant: c.2451T > A, p.(His817Gln)

      HGVS: NM_000552.5:c.2451T>A (p.His817Gln)

      ClinVarID: 100224

      CAID: CA228345

      gnomAD: MAF of 0.1150 (8626/75016 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6036483-A-T?dataset=gnomad_r4

      Variant: c.3445T > C, p.(Cys1149Arg)

      HGVS: NM_000552.5:c.3445T>C (p.Cys1149Arg)

      ClinVarID: 309

      CAID: CA228410

      gnomAD: MAF of 0.000003160 (1/316464 alleles) in European (non-Finnish) population https://gnomad.broadinstitute.org/variant/chr12-6022833-A-G?dataset=gnomad_r4

      Variant: c.4414G > C p.(Asp1472His)

      HGVS: NM_000552.5:c.4414G>C (p.Asp1472His)

      ClinVarID: 256679

      CAID: CA6402534

      gnomAD: MAF of 0.5076 (38011/74882 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019004-C-G?dataset=gnomad_r4

      Variant: c.6554G > A, p.(Arg2185Gln)

      HGVS: NM_000552.5:c.6554G>A (p.Arg2185Gln)

      ClinVarID: 100443

      CAID: CA228748

      gnomAD: MAF of 0.1927 (14427/74878 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-5993906-C-T?dataset=gnomad_r4

    4. 49 W

      Case: Patient 49, Family W (Table 1.), F/57, Afro-Caribbean

      DiseaseAssertion: VWD2M

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT = NA, FVIII:C (IU/dL) = 57, VWF:Ag (IU/dL) = 50, VWF:Act (IU/dL) = 29

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood group A+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.4315G > A, p.(Val1439Met)

      HGVS: NM_000552.5:c.4315G>A (p.Val1439Met)

      ClinVarID: 1334625

      CAID: CA6402550

      gnomAD: MAF of 0.005146 (386/75012 alleles) in African American population https://gnomad.broadinstitute.org/variant/chr12-6019103-C-T?dataset=gnomad_r4

      Variant: c.4414G > C p.(Asp1472His)

      HGVS: NM_000552.5:c.4414G>C (p.Asp1472His)

      ClinVarID: 256679

      CAID: CA6402534

      gnomAD: MAF of 0.5076 (38011/74882 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019004-C-G?dataset=gnomad_r4

    5. 18 K

      Case: Patient 18, Family K (Table 1.), F/53, Afro-Caribbean

      DiseaseAssertion: VWD2A (IIE)

      FamilyInfo: Patient 29 (F/33, Afro-Caribbean), Patient 32 (F/17, Afro-Caribbean), Patient 33 (F/49, Afro-Caribbean) also from Family K. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT =27, FVIII:C (IU/dL) = 19, VWF:Ag (IU/dL) = 16, VWF:Act (IU/dL) = 4

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood type A+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.1661del, p.(Lys554Serfs*23)

      HGVS: NM_000552.5:c.1661del (p.Lys554Serfs*23)

      ClinVarID:

      CAID: CA2617232671

      gnomAD: MAF is 0.00001332 (1/75048 alleles) in African/African/American population https://gnomad.broadinstitute.org/variant/chr12-6057916-CT-C?dataset=gnomad_r4

      Variant: c.2365A > G, p.(Thr789Ala)

      HGVS: NM_000552.5:c.2365A>G (p.Thr789Ala)

      ClinVarID: 256659

      CAID: CA6403090

      gnomAD: MAF of 0.5793 (43409/74928 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6044368-T-C?dataset=gnomad_r4

      Variant: c.2385T > C, p.(Tyr795 =)

      HGVS: NM_000552.5:c.2385T>C (p.Tyr795=)

      ClinVarID: 256660

      CAID: CA6403087

      gnomAD: MAF of 0.5788 (43385/74952 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6044348-A-G?dataset=gnomad_r4

      Variant: c.2880G > A, p.(Arg960 =)

      HGVS: NM_000552.5:c.2880G>A (p.Arg960=)

      ClinVarID: 195657

      CAID: CA201877

      gnomAD: MAF of 0.3169 (23737/74896 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6029429-C-T?dataset=gnomad_r4

      Variant: c.3505T > A, p.(Cys1169Ser)

      HGVS: NM_000552.5:c.3505T>A (p.Cys1169Ser)

      ClinVarID:

      CAID: CA383511219

      gnomAD:

      Variant: c.4414G > C p.(Asp1472His)

      HGVS: NM_000552.5:c.4414G>C (p.Asp1472His)

      ClinVarID: 256679

      CAID: CA6402534

      gnomAD: MAF of 0.5076 (38011/74882 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019004-C-G?dataset=gnomad_r4

      Variant: c.6554G > A, p.(Arg2185Gln)

      HGVS: NM_000552.5:c.6554G>A (p.Arg2185Gln)

      ClinVarID: 100443

      CAID: CA228748

      gnomAD: MAF of 0.1927 (14427/74878 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-5993906-C-T?dataset=gnomad_r4

    6. 23 I

      Case: Patient 23, Family I (Table 1.), F/86, Afro-Caribbean

      DiseaseAssertion: VWD2A (IIE)

      FamilyInfo: Patient 13 (F/65, Afro-Caribbean), Patient 21 (F/97, Afro-Caribbean), Patient 22 (F/67, Afro-Caribbean), Patient 24 (F/92, Afro-Caribbean), Patient 25 (F/62, Afro-Carribean) also from Family I. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT =16, FVIII:C (IU/dL) = 24, VWF:Ag (IU/dL) = 15, VWF:Act (IU/dL) = 14

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood group O+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.1530G > A, p.(Val510 =) p.

      HGVS: NM_000552.5:c.1530G>A (p.Val510=)

      ClinVarID:

      CAID: CA6403368

      gnomAD: MAF of 0.00002198 (2/91004 alleles) in South Asian population https://gnomad.broadinstitute.org/variant/chr12-6062957-C-T?dataset=gnomad_r4

      Variant: c.1892C > T, p.(Ala631Val)

      HGVS: NM_000552.5:c.1892C>T (p.Ala631Val)

      ClinVarID: 422844

      CAID: CA6403245

      gnomAD: MAF of 0.001908 (137/71810 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6056910-G-A?dataset=gnomad_r4

      Variant: c.2220G > A, p.(Met740Ile)

      HGVS: NM_000552.5:c.2220G>A (p.Met740Ile)

      ClinVarID: 100206

      CAID: CA201316

      gnomAD: MAF of 0.1816 (13626/75022 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6046784-C-T?dataset=gnomad_r4

      Variant: c.2451T > A, p.(His817Gln)

      HGVS: NM_000552.5:c.2451T>A (p.His817Gln)

      ClinVarID: 100224

      CAID: CA228345

      gnomAD: MAF of 0.1150 (8626/75016 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6036483-A-T?dataset=gnomad_r4

      Variant: c.3258C > T, p.(Tyr1086 =)

      HGVS: NM_000552.5:c.3258C>T (p.Tyr1086=)

      ClinVarID: 256664

      CAID: CA6402788

      gnomAD: MAF of 0.1284 (9131/71128 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6023752-G-A?dataset=gnomad_r4

      Variant: c.3445T > C, p.(Cys1149Arg)

      HGVS: NM_000552.5:c.3445T>C (p.Cys1149Arg)

      ClinVarID: 309

      CAID: CA228410

      gnomAD: MAF of 0.000003160 (1/316464 alleles) in European (non-Finnish) population https://gnomad.broadinstitute.org/variant/chr12-6022833-A-G?dataset=gnomad_r4

      Variant: c.4414G > C p.(Asp1472His)

      HGVS: NM_000552.5:c.4414G>C (p.Asp1472His)

      ClinVarID: 256679

      CAID: CA6402534

      gnomAD: MAF of 0.5076 (38011/74882 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019004-C-G?dataset=gnomad_r4

      Variant: c.6554G > A, p.(Arg2185Gln)

      HGVS: NM_000552.5:c.6554G>A (p.Arg2185Gln)

      ClinVarID: 100443

      CAID: CA228748

      gnomAD: MAF of 0.1927 (14427/74878 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-5993906-C-T?dataset=gnomad_r4

    7. 41 S

      Case: Patient 41, Family S (Table 1.), M/63, Afro-Caribbean

      DiseaseAssertion: Indeterminant

      FamilyInfo: Patient 39 (F/76, Afro-Caribbean), Patient 40 (F/38, Afro-Caribbean)and Patient 52 (F/48, Afro Caribbean) also from Family S. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT = 0, FVIII:C (IU/dL) = 100, VWF:Ag (IU/dL) = 92, VWF:Act (IU/dL) = 36

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood group O+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.4138A > G, p.(Ile1380Val)

      HGVS: NM_000552.5:c.4138A>G (p.Ile1380Val)

      ClinVarID: 310063

      CAID: CA6402595

      gnomAD: MAF of 0.1184 (8878/74958 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019280-T-C?dataset=gnomad_r4

      Variant: c.4304A > G, p.(Asn1435Ser)

      HGVS: NM_000552.5:c.4304A>G (p.Asn1435Ser)

      ClinVarID: 310062

      CAID: CA6402552

      gnomAD: MAF of 0.1124 (8427/74964 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019114-T-C?dataset=gnomad_r4

      Variant: c.4414G > C p.(Asp1472His)

      HGVS: NM_000552.5:c.4414G>C (p.Asp1472His)

      ClinVarID: 256679

      CAID: CA6402534

      gnomAD: MAF of 0.5076 (38011/74882 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019004-C-G?dataset=gnomad_r4

      Variant: c.4628C > G p.(Ser1543Cys)

      HGVS: NM_000552.5:c.4628C>G (p.Ser1543Cys)

      ClinVarID: 4533008

      CAID: CA383500651

      gnomAD:

    8. 28 F

      Case: Patient 28, Family F (Table 1.), F/55, Afro-Caribbean

      DiseaseAssertion: VWD2A (IIE)

      FamilyInfo: Patient 8 (M/86, Afro-Caribbean) and Patient 9 (F/76, Afro-Caribbean) also from Family F. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT = 6, FVIII:C (IU/dL) = 112, VWF:Ag (IU/dL) = 10, VWF:Act (IU/dL) = 14

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood group A+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.1530G > A, p.(Val510 =) p.

      HGVS: NM_000552.5:c.1530G>A (p.Val510=)

      ClinVarID:

      CAID: CA6403368

      gnomAD: MAF of 0.00002198 (2/91004 alleles) in South Asian population https://gnomad.broadinstitute.org/variant/chr12-6062957-C-T?dataset=gnomad_r4

      Variant: c.1892C > T, p.(Ala631Val)

      HGVS: NM_000552.5:c.1892C>T (p.Ala631Val)

      ClinVarID: 422844

      CAID: CA6403245

      gnomAD: MAF of 0.001908 (137/71810 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6056910-G-A?dataset=gnomad_r4

      Variant: c.2220G > A, p.(Met740Ile)

      HGVS: NM_000552.5:c.2220G>A (p.Met740Ile)

      ClinVarID: 100206

      CAID: CA201316

      gnomAD: MAF of 0.1816 (13626/75022 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6046784-C-T?dataset=gnomad_r4

      Variant: c.2451T > A, p.(His817Gln)

      HGVS: NM_000552.5:c.2451T>A (p.His817Gln)

      ClinVarID: 100224

      CAID: CA228345

      gnomAD: MAF of 0.1150 (8626/75016 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6036483-A-T?dataset=gnomad_r4

      Variant: c.3426T > C, p.(Cys1142 =)

      HGVS: NM_000552.5:c.3426T>C (p.Cys1142=)

      ClinVarID: 256668

      CAID: CA6402757

      gnomAD: MAF of 0.2077 (7935/38206 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6022852-A-G?dataset=gnomad_r4

      Variant: c.3445T > C, p.(Cys1149Arg)

      HGVS: NM_000552.5:c.3445T>C (p.Cys1149Arg)

      ClinVarID: 309

      CAID: CA228410

      gnomAD: MAF of 0.000003160 (1/316464 alleles) in European (non-Finnish) population https://gnomad.broadinstitute.org/variant/chr12-6022833-A-G?dataset=gnomad_r4

      Variant: c.3485C > T, p.(Pro1162Leu)

      HGVS: NM_000552.5:c.3485C>T (p.Pro1162Leu)

      ClinVarID: 256669

      CAID: CA6402756

      gnomAD: MAF of 0.2076 (7087/34136 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6022793-G-A?dataset=gnomad_r4

      Variant: c.3486A > G, p.(Pro1162 =)

      HGVS: NM_000552.5:c.3486A>G (p.Pro1162=)

      ClinVarID: 256670

      CAID: CA6402755

      gnomAD: MAF of 0.2083 (7074/33968 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6022792-T-C?dataset=gnomad_r4

      Variant: c.4414G > C p.(Asp1472His)

      HGVS: NM_000552.5:c.4414G>C (p.Asp1472His)

      ClinVarID: 256679

      CAID: CA6402534

      gnomAD: MAF of 0.5076 (38011/74882 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019004-C-G?dataset=gnomad_r4

      Variant: c.6554G > A, p.(Arg2185Gln)

      HGVS: NM_000552.5:c.6554G>A (p.Arg2185Gln)

      ClinVarID: 100443

      CAID: CA228748

      gnomAD: MAF of 0.1927 (14427/74878 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-5993906-C-T?dataset=gnomad_r4

    1. 1 M/10 <1 5 NR 7 c.6634T>Ca p.C2212Ra 38 Homozygous

      Case: 1, M, 10, Italian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: not reported

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (IU/dL): <1, FVIII:C (IU/dL): 5, Bleeding Score: 7

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.6634T>C (p.Cys2212Arg), Exon 38, D4 domain, Homozygous

      Note: parents investigated for the probands defects and confirmed to carry the expected mutation at the heterozygous state

    1. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders

      PMID: 31064749

      Gene: VWF

      HGNC: 12726

      Disease: von Willebrand Disease Type 2

      MONDO: 0013304

      InheritancePattern: Autosomal Dominant (for Types 2A, 2B and 2M) or Autosomal Recessive (for Type 2N)

      Prevalence: Overall VWD prevalence is estimated to be as high as 1 in 100 in the general population, with 1 in 10,000 pursuing tertiary care referral ((PMID: 28847738).

      Penetrance: Fully penetrant / nearly fully penetrant for most pathogenic variants

    1. 24*IranF/171—YesSevere6520T→GC2174G37HomozygousN.A.

      Case: 24, F, 17, Iranian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: Yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): 1, Bleeding symptoms: Severe

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      6520T→G (Cys2174Gly), Exon 37, Homozygous

    2. 12*ItalyF/15<1—NoMild8241del92748delHYC51HomozygousN.A.

      Case: 12, F, 15, Italian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: no

      ParentalGenotype:

      2748delHYC was confirmed to be in both parents

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): <1, Bleeding symptoms: Mild

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      8241del9, 2748delHisTyrCys, Exon 51, Homozygous

    3. 5ItalyF/21<1—NoSevere1946-4C→T/7630C→TFS/Q2544X16/45HeterozygousN.A./N.A.

      Case: 5 , F, 21, Italian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): <1, Bleeding symptoms: Severe

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      1946-4C→T (intronic), Exon 16

      7630C→T (Gln2544X), Exon 45

      Compound Heterozygous

      Note: Article assumes that 1946-4C→T is a frameshift mutation. No potential splice site mutation was confirmed at the mRNA level; “Splice Site Prediction program” found all mutations likely to disrupt normal splicing. No possible splice site mutation could be identified on 100 chromosomes from a group of 50 normal subjects with same genetic background as patients, excluding the possibility that these mutations represent common polymorphisms.

    4. 13IranM/8<1—YesMild139G→CD47H3HomozygousNlaIII (+)

      Case: 13, M, 8, Iranian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: Yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): <1, Bleeding symptoms: Mild

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      139G→C (Asp47His), Exon 3, Homozygous

    5. 31*IndiaM/32<1—YesSevere7130insCFS42HomozygousN.A.

      Case: 31, M, 32, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: Yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): <1, Bleeding symptoms: Severe

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant: 7130insC (FS), Exon 42, Homozygous

    6. 21*IranF/52<110YesSevere4036C→TQ1346X28HomozygousAluI (+)

      Case: 21, F, 52, Iranian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: Yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): <1, Bleeding symptoms: Severe

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: 10

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      4036C→T (Gln1346X), Exon 28, Homozygous

      Note: One unit (U) of alloantibody to VWF is the concentration that binds 50% of the VWF added to the system, with the total potency calculated as the reciprocal of the dilution containing 1 anti-VWF U (total U).

    7. 9ItalyM/34<1—YesSevere3108+5G→AFS23HomozygousMaeI (−)

      Case: 9, M, 34, Italian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): <1, Bleeding symptoms: Severe

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      3108+5G→A (Intronic), Exon 23, Homozygous

      Note: Article assumes that 3108+5G→A is a frameshift mutation. No potential splice site mutation was confirmed at the mRNA level; “Splice Site Prediction program” found all mutations likely to disrupt normal splicing. No possible splice site mutation could be identified on 100 chromosomes from a group of 50 normal subjects with same genetic background as patients, excluding the possibility that these mutations represent common polymorphisms.

    8. 32IndiaM/30<1—NoMild7130insCFS42HomozygousN.A.

      Case: 32, M, 30, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: No

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): <1, Bleeding symptoms: Mild

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      7130insC (FS), Exon 42, Homozygous

      Note: It is possible that the homozygous zygosity was detected from a PCR artifact (e.g. presence of a large gene deletion or point mutation that prevents amplification); different sets of primers were used, providing conformation and excluding the possibility for a PCR artifact due to point mutation.

    9. 25*IranM/201—YesMild7674insCFS45HomozygousBglI (−)

      Case: 25, M, 20, Iranian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: Yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): 1, Bleeding symptoms: Mild

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      7674insC (FS), Exon 45, Homozygous

    1. V‐138

      Case#: Elayaperumal_2018_V-138, F, 2 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity, family history of bleeding

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: bleeding score of 19, VWF:Ag of 0, FVIII:C of 1.9%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: Heterozygous c.3379+1G>A

      HGVS: NM_000552.3:c.3379+1G>A

      ClinVarID: 100257

      CAID: CA228398

      gnomAD: MAF 0.0001508 (3/19892 alleles, East Asian population) https://gnomad.broadinstitute.org/variant/12-6132796-C-T

      MultipleGeneVariants: Since this patient was reportedly heterozygous, they should have another variant. However, only one was reported.

    1. Case 7

      Case: Case 7, ages 2-17, Croatian

      DiseaseAssertion: VWD2B

      FamilyInfo:

      ParentalGenotypes(s):

      CasePresentingHPOs:

      CaseHPOFreeText:

      CaseNOTHPOs:

      CaseNOTHPOFreeText: bleeding score= 0, VWF:GPIbM (%)= 47.0, VWF:Ag (%)= 59.1, vWF:GPIbM/vWF:Ag ratio= 0.80, FVIII:C (%): 78, VWF: CBA (%)= 36.8

      CasePreviousTesting:

      Gene: VWF

      Variant: c.3923G>A p.Arg1308His

      HGVS: NM_000552.5:c.3923G>A

      ClinVar: 100303

      gnomAD: https://gnomad.broadinstitute.org/variant/12-6128661-C-T?dataset=gnomad_r2_1, frequency: 0.00004603

    2. Case 8

      Case: Case 8, ages 2-17, Croatian

      DiseaseAssertion: VWD2B

      FamilyInfo:

      ParentalGenotypes(s):

      CasePresentingHPOs:

      CaseHPOFreeText:

      CaseNOTHPOs:

      CaseNOTHPOFreeText: bleeding score= 3, VWF:GPIbM (%)= 16.1, VWF:Ag (%)= 57.8, vWF:GPIbM/vWF:Ag ratio= 0.28, FVIII:C (%): 61, VWF: CBA (%)= 36.4

      CasePreviousTesting:

      Gene: VWF

      Variant: c.3946G>A, p.Val1316Met

      HGVS: NM_000552.5:c.3946G>A

      ClinVar: 290

      gnomAD: not in gnomad

    1. Case: P69, Chinese, male, 12yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 3; VWF:Ag (%) = 2.8, VWF:RCo (%) = 2.5, FVIII:C (%) = 10.5, VWF:CB (%) = 3.2, VWFpp (%) = 2.7, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 1.1, VWFpp/VWF:Ag = 1.0, FVIII:C/VWF:Ag = 3.8, RIPA (1.2 mg/ml, %) = 49.7

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.484T>C (p.Cys162Arg)

      HGVS: NM_000552.3:c.484T>C (p.Cys162Arg)

      ClinVarID: NA

      CAID: CA383518153; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383518153

      gnomAD: absent

      Variant 2: c.7884C>G (.Pro2628=) - reported to be a splice site variant

      HGVS: NM_000552.5:c.7884C>G (.Pro2628=)

      ClinVarID: NA

      CAID: CA6401487; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA6401487

      gnomAD: MAF = 0.0002175 (4/18388 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6076655-G-C

    2. Case: P5, Chinese, female, 65yo

      DiseaseAssertion: VWD2N

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 14; VWF:Ag (%) = 55.2, VWF:RCo (%) = 51.4, FVIII:C (%) = 1.3, VWF:CB (%) = 58.2, VWFpp (%) = 49.3, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 1.1, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 0.0, VWF: FVIIIB (%) = 0.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.1911delC - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.2446C>T (p.Arg816Trp)

      HGVS: NM_000552.4(VWF):c.2446C>T (p.Arg816Trp)

      ClinVarID: 295; https://www.ncbi.nlm.nih.gov/clinvar/variation/295/

      CAID: NA

      gnomAD: MAF = 0.0002541 (9/35418 alleles) in the Latino/Admixed American population; https://gnomad.broadinstitute.org/variant/12-6145654-G-A?dataset=gnomad_r2_1

    3. Case: P37, Chinese, male, 20yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 10; VWF:Ag (%) = 0.6, VWF:RCo (%) = 0.5, FVIII:C (%) = 5.7, VWF:CB (%) = 0.6, VWFpp (%) = 0.7, VWF:RCo/VWF:Ag = 0.8, VWF:CB/VWF:Ag = 1.0, VWFpp/VWF:Ag = 1.2, FVIII:C/VWF:Ag = 9.5

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.1025_1032dup - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    4. Case: P85, Chinese, female, 29yo

      DiseaseAssertion: VWD2N

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 2; VWF:Ag (%) = 11.0, VWF:RCo (%) = 10.9, FVIII:C (%) = 6.5, VWF:CB (%) = 11.3, VWFpp (%) = 11.0, VWF:RCo/VWF:Ag = 1.0, VWF:CB/VWF:Ag = 1.0, VWFpp/VWF:Ag = 1.0, FVIII:C/VWF:Ag = 0.6, VWF: FVIIIB (%) = 0.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.855G>A (p.Trp285Ter)

      HGVS: NM_000552.5:c.855G>A (p.Trp285Ter)

      ClinVarID: NA

      CAID: CA383508140; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383508140

      gnomAD: absent

      Variant 2: c.2574C>G (p.Cys858Trp)

      HGVS: NM_000552.5:c.2574C>G (p.Cys858Trp)

      ClinVarID: NA

      CAID: CA232299278; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA232299278

      gnomAD: MAF = 0.0001002 (2/19954 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6143965-G-C

    5. Case: P82, Chinese, female, 80yo

      DiseaseAssertion: VWD2M

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type AB blood, bleeding score = 10; VWF:Ag (%) = 15.6, VWF:RCo (%) = 2.7, FVIII:C (%) = 50.8, VWF:CB (%) = 14.9, VWFpp (%) = 13.6, VWF:RCo/VWF:Ag = 0.2, VWF:CB/VWF:Ag = 1.0, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 3.3

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.3365C>T (p.Thr1122Met)

      HGVS: NM_000552.4(VWF):c.3365C>T (p.Thr1122Met)

      ClinVarID: 453122; https://www.ncbi.nlm.nih.gov/clinvar/variation/453122/

      CAID: NA

      gnomAD: MAF = 0.003169 (63/19880 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6132811-G-A?dataset=gnomad_r2_1

      Variant 2: c.3895del

      HGVS: NM_000552.5:c.3895del

      ClinVarID: NA

      CAID: CA603482918; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA603482918

      gnomAD: MAF = 0.00009925 (1/10076 alleles) in Ashkenazi Jewish population; https://gnomad.broadinstitute.org/variant/12-6128686-CA-C

      Variant 3: c.5668G>A (p.Gly1890Arg)

      HGVS: NM_000552.4(VWF):c.5668G>A (p.Gly1890Arg)

      ClinVarID: 672096; https://www.ncbi.nlm.nih.gov/clinvar/variation/627096/

      CAID: NA

      gnomAD: MAF = 0.00006559 (1/15246 alleles) in European (non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6120957-C-T?dataset=gnomad_r2_1

      Variant 4: c.6424C>T (p.Leu2142Phe)

      HGVS: NM_000552.5(VWF):c.6424C>T (p.Leu2142Phe)

      ClinVarID: 988881; https://www.ncbi.nlm.nih.gov/clinvar/variation/988881/

      CAID: NA

      gnomAD: absent

    6. Case: P11, Chinese, male, 56yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 8; VWF:Ag (%) = 1.5, VWF:RCo (%) = 1.7, FVIII:C (%) = 6.2, VWF:CB (%) = 1.4, VWFpp (%) = 1.3, VWF:RCo/VWF:Ag = 1.1, VWF:CB/VWF:Ag = 0.9, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 4.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.205delT - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.2791G>T (p.Gly931Ter)

      HGVS: NM_000552.5:c.2791G>T (p.Gly931Ter)

      ClinVarID: NA

      CAID: CA383517649; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383517649

      gnomAD: absent

    7. Case: P64, Chinese, female, 2yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 7; VWF:Ag (%) = 1.3, VWF:RCo (%) = 1.1, FVIII:C (%) = 4.0, VWF:CB (%) = 1.5, VWFpp (%) = 0.9, VWF:RCo/VWF:Ag = 0.8, VWF:CB/VWF:Ag = 1.2, VWFpp/VWF:Ag = 0.7, FVIII:C/VWF:Ag = 3.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.196C>T (p.Gln66Ter)

      HGVS: NM_000552.5:c.196C>T (p.Gln66Ter)

      ClinVarID: NA

      CAID: CA383507653; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383507653

      gnomAD: absent

      Variant 2: c.4457C>A (p.Ser1486Ter)

      HGVS: NM_000552.5:c.4457C>A (p.Ser1486Ter)

      ClinVarID: NA

      CAID: CA383501822; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383501822

      gnomAD: absent

    8. Case: P49, Chinese, male, 7yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 3; VWF:Ag (%) = 1.5, VWF:RCo (%) = 1.3, FVIII:C (%) = 8.0, VWF:CB (%) = 1.6, VWFpp (%) = 1.1, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 1.1, VWFpp/VWF:Ag = 0.7, FVIII:C/VWF:Ag = 5.3

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.1534-13_c.1551delinsCA - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.2968-14A>G

      HGVS: NM_000552.5:c.2968-14A>G

      ClinVarID: NA

      CAID: CA690485152; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA690485152

      gnomAD: absent

    9. Case: P15, Chinese, female, 52yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 15; VWF:Ag (%) = 1.5, VWF:RCo (%) = 1.6, FVIII:C (%) = 7.1, VWF:CB (%) = 1.1, VWFpp (%) = 1.2, VWF:RCo/VWF:Ag = 1.1, VWF:CB/VWF:Ag = 0.7, VWFpp/VWF:Ag = 0.8, FVIII:C/VWF:Ag = 4.7

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.813C>A (p.Tyr271Ter)

      HGVS: NM_000552.5:c.813C>A (p.Tyr271Ter)

      ClinVarID: NA

      CAID: CA383508534; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383508534

      gnomAD: absent

      Variant 2: c.893dup (p.Met299fs)

      HGVS: NM_000552.4(VWF):c.893dup (p.Met299fs)

      ClinVarID: 100511; https://www.ncbi.nlm.nih.gov/clinvar/variation/100511/

      CAID: NA

      gnomAD: absent

    1. P20

      Case: P20, F/33

      DiseaseAssertion: VWD1

      FamilyInfo: No family history

      ParentalGenotype: NA

      CaseHPOFreeText: The bleeding score was 4, aPTT was 25 seconds, FVIII:C was 6%, VWF:RCo was 19 IU/dL, and VWF:Ag was 19 IU/dL, with a VWF:RCo/VWF:Ag ratio of 1.0. RIPA was normal, VWF multimer analysis was not tested, and platelet count was 475 × 10⁹/L.

      CasePreviousTesting: NA

      GenotypingMethod: Direct sequencing of all exons, flanking intronic sequences, and the promoter of VWF was performed.

      Gene: VWF

      Variant: c.1135T>G, p.C379G, c.7390C>T, p.R2464C. Compound heterozygous

      HGVS: NM_000552.5(VWF):c.1135T>G (p.Cys379Gly), NM_000552.5(VWF):c.7390C>T (p.Arg2464Cys)

      ClinVar: 100467

      CAID: CA6403534 , CA228786

      gnomAD: https://gnomad.broadinstitute.org/variant/chr12-6071318-A-C?dataset=gnomad_r4, https://gnomad.broadinstitute.org/variant/chr12-5976158-G-A?dataset=gnomad_r4

    2. P19

      Case: P19, M/19

      DiseaseAssertion: VWD1

      FamilyInfo: No family history

      ParentalGenotype: NA

      CaseHPOFreeText: The bleeding score was 2, aPTT was 31 seconds, FVIII:C was 72%, VWF:RCo was 79 IU/dL, and VWF:Ag was 33 IU/dL, with a VWF:RCo/VWF:Ag ratio of 2.4. The VWF multimer pattern was normal, RIPA was not tested, and the platelet count was 239 × 10⁹/L.

      CasePreviousTesting: NA

      GenotypingMethod: Direct sequencing of all exons, flanking intronic sequences, and the promoter of VWF was performed.

      Gene: VWF

      Variant: no mutation detected

      HGVS:

      ClinVar:

      CAID:

      gnomAD:

    3. P5F/312AYes95634140.3Loss of HMW1210

      Case: P5 Female, Korean, 31 years at report

      DiseaseAssertion: VWD2A

      FamilyInfo: Positive family history, no details provided.

      ParentalGenotype: NA

      CasePresentingHPOs: HP:0030129, HP:0012147, HP:0030132, HP:0011871

      (Impaired ristocetin cofactor assay activity, Reduced quantity of VWF, Absence of large von Willebrand factor multimers, Impaired RIPA)

      CaseHPOFreeText: bleeding score 9, FVII:C 3%, VWF:Rco 4 IU/dL, VWF:Ag 14 IU/Dl, VWF:Rco/VWF:Ag 0.3, RIPA 1 ohms

      CaseNotHPOs: HP:0003645, HP:0001873

      (Prolonged partial thromboplastin time, Thrombocytopenia)

      CaseNotHPOFreeText: aPTT 36s, platelets 210x10^9/L

      CasePreviousTesting: NA

      GenotypingMethod: Direct sequencing of all exons, flanking intronic sequences, and the promoter of VWF was performed.

      Gene: VWF

      Variant: c.2574C>G p.C858W

      HGVS: NM_000552.4:c.2574C>G (p.Cys858Trp)

      ClinVar: NA

      CAID: CA232299278

      gnomAD: MAF of 0.0001002 (2/19954 alleles) in the East Asian population

      https://gnomad.broadinstitute.org/variant/12-6143965-G-C

    1. 8

      Case: Patient 8 (Family B), female, 49yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group A, Platelet count x103/μl = 178, PFA 100 sec = >300, SPA % = 9.5, MADR mg/mL = 0.75, VWF:Ag U/dL = 23.0, VWF:CB U/dL = 4.2, VWF:CB ratio = 0.19, VWF:RCo U/dL = 13.8, VWF:RCo ratio = 0.63, Platelet VWF U/dL = 74.0, FVIII U/dL = 50.0, BAT F/M = 12

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

    2. 3

      Case: Patient 3 (Family A), female, 38yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group A, Platelet count x103/μl = 207, PFA 100 sec = >300, SPA % = 0, MADR mg/mL = 0.45, VWF:Ag U/dL = 67.9, VWF:CB U/dL = 3.6, VWF:CB ratio = 0.06, VWF:RCo U/dL = 33.1, VWF:RCo ratio = 0.48, Platelet VWF U/dL = 128, FVIII U/dL = 54.5, BAT F/M = 10

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

    3. 2

      Case: Patient 2 (Family A), female, 75yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group A, Platelet count x103/μl = 322, PFA 100 sec = NA, SPA % = 10, MADR mg/mL = 0.6, VWF:Ag U/dL = 133, VWF:CB U/dL = 144.2, VWF:CB ratio = 1.1, VWF:RCo U/dL = 106, VWF:RCo ratio = 0.79, Platelet VWF U/dL = 129.5, FVIII U/dL = 126, BAT F/M = 3

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.4115T>G (p.Ile1372Ser)

      HGVS: NM_000552.4(VWF):c.4115T>G (p.Ile1372Ser)

      ClinVarID: 100327; https://www.ncbi.nlm.nih.gov/clinvar/variation/100327/

      gnomAD: MAF = 0.00006175 (7/113356 alleles) in the European (non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6128469-A-C?dataset=gnomad_r2_1

    4. 10

      Case: Patient 10 (Family C), female, 70yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group O, Platelet count x103/μl = 168, PFA 100 sec = >300, SPA % = 15, MADR mg/mL = 0.75, VWF:Ag U/dL = 44.6, VWF:CB U/dL = 10.3, VWF:CB ratio = 0.23, VWF:RCo U/dL = 21.4, VWF:RCo ratio = 0.47, Platelet VWF U/dL = 202.0, FVIII U/dL = 53.2, BAT F/M = 15

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

    1. Search for mutations in a segment of the exon 28 of the human von Willebrand factor gene: New mutations, R1315C and R1341W, associated with type 2M and 2B variants

      PMID: 9723578

      Gene: VWF

      HGNC: 12726

      Disease: von Willebrand disease type 2B

      MONDO: 0015629

      InheritancePattern: Autosomal Dominant

      Prevalence: Overall VWD prevalence is estimated to be as high as 1 in 100 in the general population, with 1 in 10,000 pursuing tertiary care referral ((PMID: 28847738).

      Penetrance: Fully penetrant / nearly fully penetrant for most pathogenic type 2 variants

    1. c.8318 G > C, p.Cys2773Ser mutation

      Case: Moreno-Castano_2021_Case_1, female, age 21 at time of study

      DiseaseAssertion: VWD2A

      FamilyInfo: The phenotypes of the affected propositus, the two unaffected parents, and the unaffected sibling are documented in Table I and Figure 1, while the family relationsihps and genotypes are not shown but described.

      ParentalGenotype(s): The parental genotypes are negative for the variant, indicating that the variant is likely de novo in the proband.

      CasePresentingHPOs: HP:0030129 (Impaired ristocetin cofactor assay activity), HP:0011871 (Impaired ristocetin-induced platelet aggregation), HP:0040225 (Decrease in high molecular weight von Willebrand factor Multimers), HP:0000978 (Bruising susceptibility), HP:0000421 (Epistaxis)

      CaseHPOFreeText: Low VWF:RCo/VWF:Ag ratio

      CaseNOTHPOs: HP:0030976 (Abnormal factor VIII activity)

      CaseNOTHPOFreeText: Normal / slightly higher VWF antigen level

      CasePreviousTesting: Because of the detailed clinical phenotype, genotyping was limited to the VWF locus alone.

      GenotypingMethod: Genotyping consisted of PCR amplification and Sanger sequencing of the 52 exons of the VWF gene, as well as linkage analysis using four STRs located within the VWF locus.

      PreviouslyPublished: The case appears to have been first published in PMID: 28971901.

      Gene: VWF

      Variant: NM_000552.5(VWF):c.8318G>C (p.Cys2773Ser)

      ClinVarID: 100503

      gnomAD: This variant is absent from gnomAD v2.1.1 and v3.1.2.

    1. Case: Patient A

      DiseaseAssertion: VWD2N

      FamilyInfo: Family 1

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0012147, HP:0030129, HP:0030130, HP:0011871

      CaseHPOFreeText: PTsec = 35.2, FVIII U/dL = 18.5, FVIII ratio = 0.29, VWF:Ag U/dL = 62.9, VWF:FVIIIB U/dL = 10.7, VWF:FVIIIB ratio = 0.17, VWF:CB U/dL = 53.3, VWF:RCo U/dL = 60.4, RIPA % = 74.7, PlatVWF:Ag U/dL = 90.4

      CaseNOTHPOs:

      CaseNOTHPOFreeText: n/a

      CasePreviousTesting: n/a

      GenotypingMethod: "Genetic analysis was performed on exons 17-20 of the VWF gene as previously described" (PMID: 12393698)

      PreviouslyPublished: n/a

      Gene: VWF

      Variant: c.2561G>A (p.Arg854Gln); homozygous

      HGVS: NM_000552.5(VWF):c.2561G>A (p.Arg854Gln)

      ClinVarID: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/?new_evidence=false

      CAID: n/a

      gnomAD: MAF (European, Finnish) = 0.005692; https://gnomad.broadinstitute.org/variant/12-6143978-C-T

    2. Case: Patient B

      DiseaseAssertion: VWD2N

      FamilyInfo: Family 2

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0012147, HP:0030129, HP:0030130, HP:0011871

      CaseHPOFreeText: PTsec = 37.2, FVIII U/dL = 36.7, FVIII ratio = 0.33, VWF:Ag U/dL = 109.8, VWF:FVIIIB U/dL = 25.7, VWF:FVIIIB ratio = 0.23, VWF:CB U/dL = 133.8, VWF:RCo U/dL = 94.5, RIPA % = 75.8, PlatVWF:Ag U/dL = 95.4

      CaseNOTHPOs:

      CaseNOTHPOFreeText: n/a

      CasePreviousTesting: n/a

      GenotypingMethod: "Genetic analysis was performed on exons 17-20 of the VWF gene as previously described" (PMID: 12393698)

      PreviouslyPublished: n/a

      Gene: VWF

      Variant: c.2561G>A (p.Arg854Gln); homozygous

      HGVS: NM_000552.5(VWF):c.2561G>A (p.Arg854Gln)

      ClinVarID: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/?new_evidence=false

      CAID: n/a

      gnomAD: MAF (European, Finnish) = 0.005692; https://gnomad.broadinstitute.org/variant/12-6143978-C-T

    1. VWD3-4‡8.3<4.05<1.0436c.319C>T§c.6151A>T§p.Gln107Terp.Arg2051TerD1D4Stop gainedStop gainedHeterozygousHeterozygous

      Case: Croatian adult patient

      DiseaseAssertion: VWD3

      FamilyInfo: No variant detected in a family member with VWD3.

      ParentalGenotype(s): Not specified

      CasePresentingHPOs: HP:0001892, HP:0011890, HP:0000132, HP:0002239, HP:0000790, HP:0001342

      CaseHPOFreeText: Reduced VWF:Ag of <4.0%, VWF:GPIbM of 8.3%, FVIII:C of 5% and VWF:CBA below 1%.

      CaseNOTHPOs: Not specified

      CaseNOTHPOFreeText: Not specified.

      CasePreviousTesting: Not reported

      GenotypingMethod: Illumina NGS, custom designed panel covering all 52 exons as well as intronic flanking regions and promoter region of VWF gene.

      PreviouslyPublished: None

      Gene: VWF

      Variant: c.319C>T

      HGVS: NM_000552.4:c.319C>T (p.Gln107Ter)

      ClinVarID: Not available

      CAID: CA383519169

      gnomAD: Not available

    1. II : 2

      Case#: F10, II:2

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: complete loss of high MWM, VWF:Ag = 40; VWF:RCo = 5; VWF:GPIbM = 16; 0.13; 0.40; 3.20

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[R1306W];[=]

      HGVS: c.3916C>T (p.Arg1306Trp)

      CAID: CA114123

      gnomAD: absent from gnomad v4.1.0

    2. III : 1

      Case#: F10, III:1

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: complete loss of high MWM, VWF:Ag = 39; VWF:RCo = 12; VWF:GPIbM = 26; 0.31; 0.67; 2.18

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[R1306W];[=]

      HGVS: c.3916C>T (p.Arg1306Trp)

      CAID: CA114123

      gnomAD: absent from gnomad v4.1.0

    1. 6 Type 2A/2N c.2560C > Tc.7448dup Np.Arg854Trpp.Tyr24832044D’-E’C3htzhtzMissenseSmall Dupl.na 9 1 7

      Case: 6

      DiseaseAssertion: type 2A/2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 9; VWF:Ac [IU/dL] = 1; FVIII:C [IU/dL] = 7

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2560C > T p.Arg854Trp

      HGVS:

      ClinVarID: not found

      CAID: CA228351

      gnomAD: 0.00001549 (25 in 1614078) no homozygotes https://gnomad.broadinstitute.org/variant/12-6034813-G-A?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.7448dup p.Tyr2483*

      ClinVarID: not found

      gnomAD: 0.000001859 (3 in 1614148) no homozygotes https://gnomad.broadinstitute.org/variant/12-5971698-G-GT?dataset=gnomad_r4

    2. 10-12Type2A (IIE)c.3296G>AN p.Cys1099Tyr 25 D3-C8-3htz Missense O/na/A131/na/26532/na/44 117

      Case: IP #10 (also in row 6 table 6)

      DiseaseAssertion: type 2A (IIE) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 131; VWF:Ac [IU/dL] = 32; FVIII:C [IU/dL] = 117

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3296G>A p.Cys1099Tyr

      HGVS:

      ClinVarID: not found

      CAID: CA383512195

      gnomAD: absent

    3. 29 Type2Ac.4145T>AN p.Leu1382Gln 28 A1 htz Missense na 19 10 35

      Case: IP #29 (also in row 15 table 6)

      DiseaseAssertion: type 2A VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 19; VWF:Ac [IU/dL] = 10; FVIII:C [IU/dL] = 35

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4145T>A p.Leu1382Gln

      HGVS:

      ClinVarID: not found

      CAID: CA383504402

      gnomAD: absent

    4. 33 Type2A(IIA)c.4513G>A p.Gly1505Arg 28 A2 htz Missense O 21 4 27

      Case: IP #33

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 21; VWF:Ac [IU/dL] = 4; FVIII:C [IU/dL] = 27

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4513G>A p.Gly1505Arg

      HGVS:

      ClinVarID: not found

      CAID: CA383501612

      gnomAD: absent

    5. 10,11 c.3922C > A p.Arg1308Ser 28 A1 htz Missense O/A 34/77 na/50 64

      Case: IP #10 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 34; VWF:Ac [IU/dL] = n/a; FVIII:C [IU/dL] = 64

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3922C>A p.Arg1308Ser

      HGVS:

      ClinVarID: not found

      CAID: CA383506203

      gnomAD: absent

    6. 7 Type2A (IIC)c.1855C>TN p.Arg619Cys 15 D2-C8-2htz Missense A 28 14 33

      Case: IP #7 (also in row 4 table 6)

      DiseaseAssertion: type 2A (IIC) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 28; VWF:Ac [IU/dL] = 14; FVIII:C [IU/dL] = 33

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.1855C>T p.Arg619Cys

      HGVS:

      ClinVarID: not found

      CAID: CA232310118

      gnomAD: 0.000005855 (9 in 1537178) no homozygotes https://gnomad.broadinstitute.org/variant/12-6056947-G-A?dataset=gnomad_r4

    7. 66 Type2Ac.7060T>GN p.Cys2354Gly 41 C2 htz Missense na 56 39 89

      Case: IP #66 (also in row 25 table 6)

      DiseaseAssertion: type 2A VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 56; VWF:Ac [IU/dL] = 39; FVIII:C [IU/dL] = 89

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.7060T>G p.Cys2354Gly

      HGVS:

      ClinVarID: not found

      CAID: CA383491801

      gnomAD: 6.196e-7 (1 in 1613900) no homozygotes https://gnomad.broadinstitute.org/variant/12-5983171-A-C?dataset=gnomad_r4

    8. 22 2N/1 c.2561G > Ac.2649C > G Np.Arg854Glnp.Tyr8832020D’-E’D3-VWD3htzhtzMissenseNonsensena 63 60 18

      Case: IP #22 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 63; VWF:Ac [IU/dL] = 60; FVIII:C [IU/dL] = 18

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.2649C>G p.Tyr883*

      CAID: CA383520036

      gnomAD: 6.195e-7 (1 in 1614176) no homozygotes https://gnomad.broadinstitute.org/variant/12-6034724-G-C?dataset=gnomad_r4

    9. 16 c.7694G > A N p.Cys2565Ser 45 C4 htz Missense na 44 31 34 CSA 39

      Case: IP #16 in type 2M VWD sub-cohort (also in row 27 table 6)

      DiseaseAssertion: type 2M VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 44; VWF:Ac [IU/dL] = 31; FVIII:C [IU/dL] = 34; VWF:CB (IU/dL) = 39

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.7694G>A p.Cys2565Ser

      HGVS:

      ClinVarID: not found

      CAID: CA383489277

      gnomAD: absent

    10. 10-12Type2A (IIE)c.3296G>AN p.Cys1099Tyr 25 D3-C8-3htz Missense O/na/A131/na/26532/na/44 117OSCA/na/183

      Case: IP #12 (also in row 6 table 6)

      DiseaseAssertion: type 2A (IIE) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 265; VWF:Ac [IU/dL] = 44; FVIII:C [IU/dL] = 183

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3296G>A p.Cys1099Tyr

      HGVS:

      ClinVarID: not found

      CAID: CA383512195

      gnomAD: absent

    1. Management of pregnancy in type 2B von Willebrand disease: case report and literature review

      PMID: 25431025

      Gene: VWF

      HGNC: 12726

      Disease: von Willebrand disease type 2B

      MONDO: 0015629

      InheritancePattern: Autosomal Dominant

      Prevalence: Overall VWD prevalence is estimated to be as high as 1 in 100 in the general population, with 1 in 10,000 pursuing tertiary care referral ((PMID: 28847738).

      Penetrance: Fully penetrant / nearly fully penetrant for most pathogenic type 2 variants

    1. Type 2M von Willebrand Disease: F606I and I662F Mutations in the Glycoprotein Ib Binding Domain Selectively Impair Ristocetin- but not Botrocetin-Mediated Binding of von Willebrand Factor to Platelets

      PMID: 9473222

      Gene: VWF

      HGNC: 12726

      Disease: von Willebrand disease type 2M

      MONDO: 0015630

      InheritancePattern: Autosomal Dominant

      Prevalence: Overall VWD prevalence is estimated to be as high as 1 in 100 in the general population, with 1 in 10,000 pursuing tertiary care referral (PMID: 28847738).

      Penetrance: Fully penetrant / nearly fully penetrant for most pathogenic type 2 variants

    1. rs617505986127570c.5014G > A28p.G1672R30.000712A

      Case:n.a.

      DiseaseAssertion:VWD 2A

      FamilyInfo:n.a.

      ParentalGenotype(s):n.a.

      CasePresentingHPOs:n.a.

      CaseHPOFreeRext:n.a.

      CaseNOTHPOs:n.a.

      CaseNOTHPOFreeText:n.a.

      CasePreviousTesting:n.a.

      GenotypingMethod:n.a.

      PreviouslyPublished: If applicable.n.a.

      Gene: VWF

      Variant:c.5014G > A

      HGVS:NM_000552.5(VWF):c.5014G>A (p.Gly1672Arg)

      ClinVarID:100414

      CAID:n.a.

      gnomAD:n.a.

    1. Molecular diagnosis of von Willebrand disease L. Baronciani Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and Luigi Villa Foundation, Milan, ItalySearch for more papers by this author A. Goodeve Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UKSearch for more papers by this author F. Peyvandi Corresponding Author flora.peyvandi@unimi.it orcid.org/http://orcid.org/0000-0001-7423-9864 Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and Luigi Villa Foundation, Milan, Italy Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy Correspondence: Flora Peyvandi, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and Luigi Villa Foundation; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, via Pace 9, 20122 Milan, Italy. Tel.: +39 02 5503 4456; fax: +39 02 5410 0125; e‐mail: flora.peyvandi@unimi.itSearch for more papers by this author

      PMID: 28220580

      Gene: VWF

      HGNCID: 12726

    1. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population

      PMID: 22197721

      Gene: VWF

      HGNC: 12726

      Disease: von Willebrand Disease Type 2N

      MONDO: 0015631

      InheritancePattern: Autosomal Recessive

      Prevalence: Various sources (PMID: 28847738, PMID:19809303, PMID:29115006) can be combined to estimate the prevalence of VWD Type 2N between 1:15,000 and 1:80,000.

      Penetrance: VWD type 2 is fully penetrant / nearly fully penetrant for most pathogenic variants.

    1. The proband

      Case#: 1, Male, Age 12, Caucasian (Proband), Blood type O

      Disease Assertion: VWD2M

      FamilyInfo: Mother with clinical symptoms (see case #2). 40 year old father and sister had no bleeding symptoms. Parents had a non-consanguineous relationship, Table 1

      Parental Genotype: Heterozygous mother, normal father

      CasePresentingHPOs: HP:0000421, HP:0000978, HP:0004846, HP:0000225

      (Epistaxis, Bruising susceptibility, Prolonged bleeding after surgery, Gingival bleeding)

      CaseHPOFreeText: Bleeding in the central nervous system, Epistaxis required tamponades, bleeding score 14, VWF:RCo: 9 IU/dL, VWF:Ag: 17 IU/dL, RCo/Ag: 0.53, Absence of response to DDAVP infusion

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: Forward and reverse strands sequenced by automated sequencing technology, PCR techniques used to analyze exons 17, 26-31, and 52 of VWF gene

      Gene: VWF

      Variant: NM_000552.3:c.4276C>T (p.Arg1426Cys) and NM_000552.3:c.4944del (p.Ile1649Serfs?)

      ClinVar: 100407 (for c.4944delT) ClinVarID website

      CAID: CA6402561 and CA228684

      CA6402561 CA228684

      gnomAD: MAF of 0.00006152 (1/16254 alleles) in the African population for CA6402561. MAF of 0.00005440 (1/18384 alleles) in the East Asian population for CA228684.

      gnomAD website1 gnomAD website2

    1. Compromised Shear-Dependent Cleavage of Type 2N von Willebrand Factor Variants by ADAMTS13 in the Presence of Factor VIII

      PMID: 23636243

      Gene: VWF

      HGNC: 12726

      Disease: von Willebrand Disease Type 2N

      MONDO: 0015631

      InheritancePattern: Autosomal Recessive

      Prevalence: Various sources (PMID: 28847738, PMID:19809303, PMID:29115006) can be combined to estimate the prevalence of VWD Type 2N between 1:15,000 and 1:80,000.

      Penetrance: VWD type 2 is fully penetrant / nearly fully penetrant for most pathogenic variants.

    1. First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease

      PMID: 25851809

      Gene: VWF

      HGNC: 12726

      Disease: von Willebrand disease type 2B

      MONDO: 0015629

      InheritancePattern: Autosomal Dominant

      Prevalence: Overall VWD prevalence is estimated to be as high as 1 in 100 in the general population, with 1 in 10,000 pursuing tertiary care referral ((PMID: 28847738).

      Penetrance: Fully penetrant / nearly fully penetrant for most pathogenic type 2 variants

    1. 6

      Case#: 6, male, 20yo

      DiseaseAssertion: VWD1

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0004846, HP:0012147, HP:0030129, HP:0030130 (Epistaxis, Reduced quantity of VWF, Impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity)

      CaseHPOFreeText: posttraumatic muscle and joint bleeds, Type O blood, VWF:Ag (0·55–2 iu/ml) pre = 0·34, VWF:RCo (0·55–2 iu/ml) pre = 0·24, FVIII:C (0·55–2 iu/ml) pre = 0·24, FVIII:C/VWF:Ag ratio = 0·71, VWF:FVIII binding (>20%) = 16%, VWF:FVIII binding/VWF:Ag (>0·7) = 0·47

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: RFLP; confirmatory sequencing

      Gene: VWF

      Variant 1: NM_000552.4(VWF):c.2561G>A (p.Arg854Gln)

      ClinVar: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/

      gnomAD: MAF = 0.005692 (European Non-Finnish); https://gnomad.broadinstitute.org/variant/12-6143978-C-T

      Variant 2: N/A - stated to be a compound heterozygote for a 2N VWD and a presumed null mutation